Pressure BioSciences (PBIO) 10-Q 14 Aug 20 2020 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2020	Aug. 14, 2020
Document And Entity Information
Entity Registrant Name	PRESSURE BIOSCIENCES INC
Entity Central Index Key	0000830656
Document Type	10-Q
Document Period End Date	Jun. 30, 2020
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business Flag	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		0
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2020

Consolidated Balance Sheets (Un

Consolidated Balance Sheets (Unaudited) - USD ($)	Jun. 30, 2020	Dec. 31, 2019
CURRENT ASSETS
Cash and cash equivalents	$ 41,458	$ 29,625
Accounts receivable	121,306	229,402
Inventories, net of $342,496 reserve at June 30, 2020 and December 31, 2019	614,863	617,716
Loan receivable	531,250
Prepaid expenses and other current assets	192,605	213,549
Total current assets	1,501,482	1,090,292
Investment in equity securities	362,905	16,643
Property and equipment, net	26,275	55,590
Right of use asset leases	40,659	76,586
Intangible assets, net	533,654	576,923
TOTAL ASSETS	2,464,975	1,816,034
CURRENT LIABILITIES
Accounts payable	809,837	815,764
Accrued employee compensation	392,425	451,200
Accrued professional fees and other	1,866,083	1,658,452
Accrued interest	5,076,790	2,949,621
Deferred revenue	36,888	23,248
Operating lease liability	40,659	76,586
Convertible debt, net of unamortized discounts of $3,923,549 and $619,227, respectively	6,224,450	6,121,338
Other debt, net of unamortized discounts of $0 and $1,769, respectively	1,577,328	1,675,667
Other related party debt	90,000	81,500
Total current liabilities	16,114,460	13,853,376
LONG TERM LIABILITIES
Long term debt	527,039
Deferred revenue	35,462	18,065
TOTAL LIABILITIES	16,676,961	13,871,441
COMMITMENTS AND CONTINGENCIES (Note 4)
STOCKHOLDERS' DEFICIT
Common stock, $.01 par value; 100,000,000 shares authorized; 3,207,285 and 2,549,620 shares issued and outstanding on June 30, 2020 and December 31, 2019 respectively	32,072	25,496
Warrants to acquire common stock	26,527,615	22,599,177
Additional paid-in capital	47,413,735	44,261,105
Accumulated deficit	(88,186,500)	(78,942,277)
Total stockholders' deficit	(14,211,986)	(12,055,407)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	2,464,975	1,816,034
Series D Convertible Preferred Stock [Member]
STOCKHOLDERS' DEFICIT
Convertible Preferred Stock, value	3	3
Series G Convertible Preferred Stock [Member]
STOCKHOLDERS' DEFICIT
Convertible Preferred Stock, value	806	806
Series H Convertible Preferred Stock [Member]
STOCKHOLDERS' DEFICIT
Convertible Preferred Stock, value	100	100
Series H2 Convertible Preferred Stock [Member]
STOCKHOLDERS' DEFICIT
Convertible Preferred Stock, value
Series J Convertible Preferred Stock [Member]
STOCKHOLDERS' DEFICIT
Convertible Preferred Stock, value	35	35
Series K Convertible Preferred Stock [Member]
STOCKHOLDERS' DEFICIT
Convertible Preferred Stock, value	68	68
Series AA Convertible Preferred Stock [Member]
STOCKHOLDERS' DEFICIT
Convertible Preferred Stock, value	$ 80	$ 80

Consolidated Balance Sheets (_2

Consolidated Balance Sheets (Unaudited) (Parenthetical) - USD ($)	Jun. 30, 2020	Dec. 31, 2019
Accounts receivable reserve	$ 0	$ 0
Inventories reserve	342,496	342,496
Convertible debt, current unamortized discounts	3,923,549	619,227
Other debt, unamortized discounts net	$ 0	$ 1,769
Convertible preferred stock, par value	$ 0.01
Convertible preferred stock, authorized	1,000,000
Convertible preferred stock, shares issued	1,000,000
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	3,207,285	2,549,620
Common stock, shares outstanding	3,207,285	2,549,620
Series D Convertible Preferred Stock [Member]
Convertible preferred stock, par value	$ 0.01	$ 0.01
Convertible preferred stock, authorized	850	850
Convertible preferred stock, shares issued	300	300
Convertible preferred stock, shares outstanding	300	300
Convertible preferred stock, liquidation value	$ 300,000	$ 300,000
Series G Convertible Preferred Stock [Member]
Convertible preferred stock, par value	$ 0.01	$ 0.01
Convertible preferred stock, authorized	240,000	240,000
Convertible preferred stock, shares issued	80,570	80,570
Convertible preferred stock, shares outstanding	80,570	80,570
Series H Convertible Preferred Stock [Member]
Convertible preferred stock, par value	$ 0.01	$ 0.01
Convertible preferred stock, authorized	10,000	10,000
Convertible preferred stock, shares issued	10,000	10,000
Convertible preferred stock, shares outstanding	10,000	10,000
Series H2 Convertible Preferred Stock [Member]
Convertible preferred stock, par value	$ 0.01	$ 0.01
Convertible preferred stock, authorized	21	21
Convertible preferred stock, shares issued	21	21
Convertible preferred stock, shares outstanding	21	21
Series J Convertible Preferred Stock [Member]
Convertible preferred stock, par value	$ 0.01	$ 0.01
Convertible preferred stock, authorized	6,250	6,250
Convertible preferred stock, shares issued	3,458	3,458
Convertible preferred stock, shares outstanding	3,458	3,458
Series K Convertible Preferred Stock [Member]
Convertible preferred stock, par value	$ 0.01	$ 0.01
Convertible preferred stock, authorized	15,000	15,000
Convertible preferred stock, shares issued	6,880	6,880
Convertible preferred stock, shares outstanding	6,880	6,880
Series AA Convertible Preferred Stock [Member]
Convertible preferred stock, par value	$ 0.01	$ 0.01
Convertible preferred stock, authorized	10,000	10,000
Convertible preferred stock, shares issued	7,939	7,939
Convertible preferred stock, shares outstanding	7,939	7,939

Consolidated Statements of Oper

Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Revenue:
Total revenue	$ 268,154	$ 518,663	$ 522,027	$ 1,028,903
Costs and expenses:
Cost of products and services	134,882	304,172	310,028	613,884
Research and development	294,602	291,538	560,292	556,242
Selling and marketing	162,098	186,609	351,214	374,824
General and administrative	1,007,215	1,136,768	2,026,225	2,281,189
Total operating costs and expenses	1,598,797	1,919,087	3,247,759	3,826,139
Operating loss	(1,330,643)	(1,400,424)	(2,725,732)	(2,797,236)
Other (expense) income:
Interest expense, net	(1,724,879)	(1,074,488)	(3,296,679)	(1,587,194)
Unrealized gain on investment in equity securities	196,891		346,262
Loss on extinguishment of liabilities	(1,710,151)	(106,461)	(2,846,518)	(147,271)
Other expense		(185,469)		(290,314)
Total other expense	(3,238,139)	(1,366,418)	(5,796,935)	(2,024,779)
Net loss	(4,568,782)	(2,766,842)	(8,522,667)	(4,822,015)
Deemed dividend on beneficial conversion feature		(889,532)		(1,949,731)
Preferred stock dividends	(396,970)	(420,489)	(721,556)	(776,099)
Net loss attributable to common stockholders	$ (4,965,752)	$ (4,076,863)	$ (9,244,223)	$ (7,547,845)
Basic and diluted net loss per share attributable to common stockholders	$ (1.70)	$ (2.22)	$ (3.34)	$ (4.24)
Weighted average common stock shares outstanding used in the basic and diluted net loss per share calculation	2,914,659	1,837,913	2,765,132	1,780,881
Products, Services, Other [Member]
Revenue:
Total revenue	$ 268,154	$ 518,663	$ 522,027	$ 1,028,903

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (8,522,667)	$ (4,822,015)
Adjustments to reconcile net loss to net cash used in operating activities:
Non-cash lease expense	35,927	28,053
Common stock issued for interest and extension fees	159,784
Depreciation and amortization	74,247	47,180
Accretion of interest and amortization of debt discount	1,750,911	290,040
Issuance of incentive shares and common stock warrants		168,000
Loss on extinguishment of accrued liabilities and debt	977,622	147,271
Stock-based compensation expense	307,110	607,574
Gain on investment in equity securities	(346,262)
Common stock issued for services	87,963
Changes in operating assets and liabilities:
Accounts receivable	108,096	64,217
Inventories	2,853	20,673
Prepaid expenses and other assets	20,944	43,077
Accounts payable	(5,927)	152,275
Accrued employee compensation	(58,775)	(18,323)
Operating lease liability	(35,927)	(28,053)
Deferred revenue and other accrued expenses	2,643,607	(172)
Net cash used in operating activities	(2,800,494)	(3,300,203)
CASH FLOWS FROM INVESTING ACTIVITIES:
Advance on Loan receivable	(531,250)
Purchases of property plant and equipment	(1,663)	(28,915)
Net cash used in investing activities	(532,913)	(28,915)
CASH FLOWS FROM FINANCING ACTIVITIES:
Net proceeds from Series AA Convertible Preferred Stock		2,292,300
Net proceeds from convertible debt	4,422,600	3,339,050
Net proceeds from non-convertible debt - third party	990,539	1,211,500
Net proceeds from non-convertible debt - related party	8,500	125,000
Payments on convertible debt	(1,257,250)	(2,533,985)
Payments on non-convertible debt - related party		(125,000)
Payments on non-convertible debt	(819,149)	(964,932)
Net cash provided by financing activities	3,345,240	3,343,933
NET INCREASE IN CASH	11,833	14,815
CASH AND CASH EQUIVALENTS AT BEGINNING OF YEAR	29,625	103,118
CASH AND CASH EQUIVALENTS AT END OF PERIOD	41,458	117,933
SUPPLEMENTAL INFORMATION
Interest paid in cash	419,817	1,162,557
NON CASH TRANSACTIONS:
Interest added to principal	152,552
Common stock issued to settle accrued liabilities	127,855
Common stock issued with debt		167,359
Discount from warrants issued with debt	2,958,693
Common stock issued in lieu of cash for dividend	176,748	151,993
Preferred stock dividends	721,556	776,099
Conversion of debt and interest into common stock	1,317,649
Discount due to beneficial conversion feature	982,097
Deemed dividend-beneficial conversion feature		$ 1,949,731

Consolidated Statements of Chan

Consolidated Statements of Changes in Stockholders' Deficit (Unaudited) - USD ($)	Series D Preferred Stock [Member]	Series G Preferred Stock [Member]	Series H Preferred Stock [Member]	Series H (2) Preferred Stock [Member]	Series J Preferred Stock [Member]	Series K Preferred Stock [Member]	Series AA Preferred Stock [Member]	Common Stock [Member]	Stock Warrants [Member]	Additional Paid-In Capital [Member]	Accumulated Other Comprehensive Loss [Member]	Accumulated Deficit [Member]	Total
Balance at Dec. 31, 2018	$ 3	$ 806	$ 100		$ 35	$ 68	$ 65	$ 16,842	$ 19,807,247	$ 39,777,301		$ (65,727,538)	$ (6,125,071)
Balance, shares at Dec. 31, 2018	300	80,570	10,000	21	3,458	6,880	6,499	1,684,184
Stock-based compensation										245,392			245,392
Series AA preferred stock dividend												(355,610)	(355,610)
Issuance of common stock for services								$ 500		167,500			168,000
Issuance of common stock for services, shares								50,000
Beneficial conversion feature on Series AA convertible preferred stock										1,060,199			1,060,199
Deemed dividend-beneficial conversion feature										(1,060,199)			(1,060,199)
Preferred Stock offering							$ 6		738,528	661,466			1,400,000
Preferred Stock offering, shares							560
Offering costs for issuance of preferred stock									160,764	(300,764)			(140,000)
Common Stock issued for debt extension								$ 163		38,824			38,988
Common Stock issued for debt extension, shares								16,350
Stock issued with debt								$ 180		50,553			50,733
Stock issued with debt, shares								17,958
Net loss												(2,055,173)	(2,055,173)
Balance at Mar. 31, 2019	$ 3	$ 806	$ 100		$ 35	$ 68	$ 71	$ 17,685	20,706,539	40,640,273		(68,138,321)	(6,772,741)
Balance, shares at Mar. 31, 2019	300	80,570	10,000	21	3,458	6,880	7,059	1,768,492
Balance at Dec. 31, 2018	$ 3	$ 806	$ 100		$ 35	$ 68	$ 65	$ 16,842	19,807,247	39,777,301		(65,727,538)	(6,125,071)
Balance, shares at Dec. 31, 2018	300	80,570	10,000	21	3,458	6,880	6,499	1,684,184
Stock issued with debt													$ 156,322
Stock issued with debt, shares													65,377
Net loss													$ (4,822,015)
Balance at Jun. 30, 2019	$ 3	$ 806	$ 100		$ 35	$ 68	$ 76	$ 18,896	21,446,642	41,676,926		(71,325,652)	(8,182,100)
Balance, shares at Jun. 30, 2019	300	80,570	10,000	21	3,458	6,880	7,518	1,889,616
Balance at Mar. 31, 2019	$ 3	$ 806	$ 100		$ 35	$ 68	$ 71	$ 17,685	20,706,539	40,640,273		(68,138,321)	(6,772,741)
Balance, shares at Mar. 31, 2019	300	80,570	10,000	21	3,458	6,880	7,059	1,768,492
Stock-based compensation										362,182			362,182
Series AA preferred stock dividend												(420,489)	(420,489)
Beneficial conversion feature on Series AA convertible preferred stock										889,532			889,532
Deemed dividend-beneficial conversion feature										(889,532)			(889,532)
Preferred Stock offering							$ 5		608,852	538,062			1,146,919
Preferred Stock offering, shares							459
Offering costs for issuance of preferred stock									131,251	(245,870)			(114,619)
Isssuance of Common Stock for Dividends Paid-in-kind								$ 425		151,568			151,993
Isssuance of Common Stock for Dividends Paid-in-kind, shares								42,456
Common Stock issued for debt extension								$ 490		125,418			125,908
Common Stock issued for debt extension, shares								49,027
Stock issued with debt								$ 296		105,293			105,589
Stock issued with debt, shares								29,641
Net loss												(2,766,842)	(2,766,842)
Balance at Jun. 30, 2019	$ 3	$ 806	$ 100		$ 35	$ 68	$ 76	$ 18,896	21,446,642	41,676,926		(71,325,652)	(8,182,100)
Balance, shares at Jun. 30, 2019	300	80,570	10,000	21	3,458	6,880	7,518	1,889,616
Balance at Dec. 31, 2019	$ 3	$ 806	$ 100		$ 35	$ 68	$ 80	$ 25,496	22,599,177	44,261,105		(78,942,277)	(12,055,407)
Balance, shares at Dec. 31, 2019	300	80,570	10,000	21	3,458	6,880	7,939	2,549,620
Stock-based compensation										241,769			241,769
Series AA preferred stock dividend												(324,586)	(324,586)
Issuance of common stock for debt extension and interest paid-in-kind								$ 385		60,175			60,560
Issuance of common stock for debt extension and interest paid-in-kind, shares								38,521
Issuance of common stock for settle accrued liabilities								$ 665		127,190			127,855
Issuance of common stock for settle accrued liabilities, shares								66,500
Common stock issued for debt settlement								$ 100		24,900			25,000
Common stock issued for debt settlement, shares								10,000
Beneficial conversion feature on debt										404,608			404,608
Warrants issued with debt										1,205,010			1,205,010
Warrants issued issued for debt extension									609,143				609,143
Net loss												(3,953,885)	(3,953,855)
Balance at Mar. 31, 2020	$ 3	$ 806	$ 100		$ 35	$ 68	$ 80	$ 26,646	24,413,330	45,119,747		(83,220,748)	(13,659,933)
Balance, shares at Mar. 31, 2020	300	80,570	10,000	21	3,458	6,880	7,939	2,664,641
Balance at Dec. 31, 2019	$ 3	$ 806	$ 100		$ 35	$ 68	$ 80	$ 25,496	22,599,177	44,261,105		(78,942,277)	(12,055,407)
Balance, shares at Dec. 31, 2019	300	80,570	10,000	21	3,458	6,880	7,939	2,549,620
Net loss													(8,522,667)
Balance at Jun. 30, 2020	$ 3	$ 806	$ 100		$ 35	$ 68	$ 80	$ 32,072	26,527,615	47,413,735		(88,186,500)	(14,211,986)
Balance, shares at Jun. 30, 2020	300	80,570	10,000	21	3,458	6,880	7,939	3,207,285
Balance at Mar. 31, 2020	$ 3	$ 806	$ 100		$ 35	$ 68	$ 80	$ 26,646	24,413,330	45,119,747		(83,220,748)	(13,659,933)
Balance, shares at Mar. 31, 2020	300	80,570	10,000	21	3,458	6,880	7,939	2,664,641
Stock-based compensation										65,341			65,341
Series AA preferred stock dividend												(396,970)	(396,970)
Issuance of common stock for services								$ 250		87,713			87,963
Issuance of common stock for services, shares								25,000
Issuance of common stock for debt extension and interest paid-in-kind								$ 425		98,799			99,224
Issuance of common stock for debt extension and interest paid-in-kind, shares								42,510
Beneficial conversion feature limited to Gross Proceeds										577,489			577,489
Isssuance of Common Stock for Dividends Paid-in-kind								$ 64,388		176,104			176,748
Isssuance of Common Stock for Dividends Paid-in-kind, shares								64,388
Warrants issued with debt									1,753,683				1,753,683
Warrants issued issued for debt extension									360,602				360,602
Conversion of debt and interest for common stock								$ 4,107		1,288,542			1,292,649
Conversion of debt and interest for common stock, shares								410,746
Net loss												(4,568,782)	(4,568,782)
Balance at Jun. 30, 2020	$ 3	$ 806	$ 100		$ 35	$ 68	$ 80	$ 32,072	$ 26,527,615	$ 47,413,735		$ (88,186,500)	$ (14,211,986)
Balance, shares at Jun. 30, 2020	300	80,570	10,000	21	3,458	6,880	7,939	3,207,285

Business Overview, Liquidity an

Business Overview, Liquidity and Management Plans	6 Months Ended
	Jun. 30, 2020
Convertible Debt On March 26, 2015
Business Overview, Liquidity and Management Plans	1) Business Overview, Liquidity and Management Plans Pressure Biosciences, Inc. (“we”, “our”, “the Company”) develops and sells innovative, broadly enabling, pressure-based platform solutions for the worldwide life sciences industry. Our solutions are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or “PCT”) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions (e.g., cell lysis, biomolecule extraction). Our primary focus is in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of our pressure-based technologies in the following areas: (1) the use of our recently acquired, patented technology from BaroFold, Inc. (the “BaroFold” technology) to allow entry into the bio-pharma contract services sector, and (2) the use of our recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies.

Going Concern

Going Concern	6 Months Ended
	Jun. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Going Concern	2) Going Concern The accompanying financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the liquidation of liabilities in the normal course of business. However, we have experienced negative cash flows from operations with respect to our pressure cycling technology business since our inception. As of June 30, 2020, we do not have adequate working capital resources to satisfy our current liabilities and as a result, there is substantial doubt regarding our ability to continue as a going concern. We have been successful in raising debt and equity capital in the past and as described in Notes 6 and 7. In addition we raised debt and equity capital after June 30, 2020 as described in Note 8. We have financing efforts in place to continue to raise cash through debt and equity offerings. Although we have successfully completed financings and reduced expenses in the past, we cannot assure you that our plans to address these matters in the future will be successful. These financial statements do not include any adjustments that might result from this uncertainty.

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2020
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	3) Summary of Significant Accounting Policies Basis of Presentation The unaudited interim financial statements of Pressure BioSciences, Inc. and its consolidated subsidiaries (collectively, the “Company”) included herein have been prepared by the Company in accordance with the instructions to Form 10-Q and the rules and regulations of the U.S. Securities and Exchange Commission. Under these rules and regulations, some information and footnote disclosures normally included in financial statements prepared under accounting principles generally accepted in the United States of America have been shortened or omitted. Management believes that all adjustments necessary for a fair statement of the financial position and the results of operations for the periods shown have been made. All adjustments are normal and recurring. These financial statements should be read together with the Company’s audited financial statements included in its Form 10-K for the fiscal year ended December 31, 2019. Use of Estimates The Company’s consolidated financial statements and accompanying notes are prepared in accordance with accounting principles generally accepted in the United States of America, which require the use of estimates, judgements and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the periods presented. Global concerns about the COVID-19 pandemic have adversely affected, and we expect will continue to adversely affect, our business, financial condition and results of operations including the estimates and assumptions made by management. Significant estimates and assumptions include valuations of share-based awards, investments in equity securities and intangible asset impairment. Actual results could differ from the estimates, and such differences may be material to the Company’s consolidated financial statements. Principles of Consolidation The consolidated financial statements include the accounts of Pressure BioSciences, Inc., and its wholly-owned subsidiary PBI BioSeq, Inc. All intercompany accounts and transactions have been eliminated in consolidation. Recent Accounting Pronouncements In June 2016, the FASB issued ASU 2016-13, Measurement of Credit Losses on Financial Instruments. The standard is effective for the Company for interim and annual periods beginning after December 15, 2022. The Company is evaluating the impact of this standard on its Consolidated Financial Statements. In December 2019, the FASB, issued ASU 2019-12, Simplifying the Accounting for Income Taxes. The standard is effective for the Company for interim and annual periods beginning after December 15, 2020 for the Company and for annual periods beginning after December 15, 2021 and interim periods beginning after December 15, 2022. The Company is evaluating the impact of this standard on its Consolidated Financial Statements. Revenue Recognition We recognize revenue in accordance with FASB ASC 606, Revenue from Contracts with Customers, ASC 340-40, Other Assets and Deferred Costs—Contracts with Customers We identify a performance obligation as distinct if both the following criteria are true: the customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer and the entity’s promise to transfer the good or service to the customer is separately identifiable from other promises in the contract. Determining the standalone selling price (“SSP”) and allocation of consideration from a contract to the individual performance obligations, and the appropriate timing of revenue recognition, is the result of significant qualitative and quantitative judgments. Management considers a variety of factors such as historical sales, usage rates, costs, and expected margin, which may vary over time depending upon the unique facts and circumstances related to each performance obligation in making these estimates. While changes in the allocation of the SSP between performance obligations will not affect the amount of total revenue recognized for a particular contract, any material changes could impact the timing of revenue recognition, which would have a material effect on our financial position and result of operations. This is because the contract consideration is allocated to each performance obligation, delivered or undelivered, at the inception of the contract based on the SSP of each distinct performance obligation. Taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction, that are collected by the Company from a customer, are excluded from revenue. Shipping and handling costs associated with outbound freight after control over a product has transferred to a customer are accounted for as a fulfillment cost and are in included in cost of revenues as consistent with treatment in prior periods. Our current Barocycler® instruments require a basic level of instrumentation expertise to set-up for initial operation. To support a favorable first experience for our customers, upon customer request, and for an additional fee, will send a highly trained technical representative to the customer site to install Barocycler®s that we sell, lease, or rent through our domestic sales force. The installation process includes uncrating and setting up the instrument, followed by introductory user training. Our sales arrangements do not provide our customers with a right of return. Any shipping costs billed to customers are recognized as revenue. The majority of our instrument and consumable contracts contain pricing that is based on the market price for the product at the time of delivery. Our obligations to deliver product volumes are typically satisfied and revenue is recognized when control of the product transfers to our customers. Concurrent with the transfer of control, we typically receive the right to payment for the shipped product and the customer has significant risks and rewards of ownership of the product. Payment terms require customers to pay shortly after delivery and do not contain significant financing components. We apply ASC 845, “Accounting for Non-Monetary Transactions”, to account for products and services sold through non-cash transactions based on the fair values of the products and services involved, where such values can be determined. Non-cash exchanges would require revenue to be recognized at recorded cost or carrying value of the assets or services sold if any of the following conditions apply: a) The fair value of the asset or service involved is not determinable. b) The transaction is an exchange of a product or property held for sale in the ordinary course of business for a product or property to be sold in the same line of business to facilitate sales to customers other than the parties to the exchange. c) The transaction lacks commercial substance. We currently record revenue for its non-cash transactions at recorded cost or carrying value of the assets or services sold. In accordance with FASB ASC 842, Leases We record revenue over the life of the lease term and we record depreciation expense on a straight-line basis over the thirty-six-month estimated useful life of the Barocycler® instrument. The depreciation expense associated with assets under lease agreement is included in the “Cost of PCT products and services” line item in our accompanying consolidated statements of operations. Many of our lease and rental agreements allow the lessee to purchase the instrument at any point during the term of the agreement with partial or full credit for payments previously made. We pay all maintenance costs associated with the instrument during the term of the leases. Revenue from government grants is recorded when expenses are incurred under the grant in accordance with the terms of the grant award. Deferred revenue represents amounts received from grants and service contracts for which the related revenues have not been recognized because one or more of the revenue recognition criteria have not been met. Revenue from service contracts is recorded ratably over the length of the contract. Disaggregation of revenue In the following table, revenue is disaggregated by primary geographical market, major product line, and timing of revenue recognition. In thousands of US dollars ($) Three Months Ended Six Months Ended Primary geographical markets 2020 2019 2020 2019 North America $ 162 $ 368 $ 307 $ 592 Europe 3 54 4 94 Asia 103 97 211 343 $ 268 $ 519 $ 522 $ 1,029 Three Months Ended Six Months Ended Major products/services lines 2020 2019 2020 2019 Hardware $ 122 $ 212 $ 217 $ 352 Consumables 51 91 107 153 Contract research services 34 111 44 349 Sample preparation accessories 33 35 58 35 Technical support/extended service contracts 17 28 36 67 Shipping and handling 6 14 15 19 Other 5 28 45 54 $ 268 $ 519 $ 522 $ 1,029 Three Months Ended Six Months Ended Timing of revenue recognition 2020 2019 2020 2019 Products transferred at a point in time $ 217 $ 506 $ 442 $ 1,007 Services transferred over time 51 13 80 22 $ 268 $ 519 $ 522 $ 1,029 Contract balances In thousands of US dollars ($) June 30, 2020 December 31, 2019 Receivables, which are included in ‘Accounts Receivable’ $ 121 $ 229 Contract liabilities (deferred revenue) 72 41 Transaction price allocated to the remaining performance obligations The following table includes estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) at the end of the reporting period. In thousands of US dollars ($) 2020 2021 2022 Total Extended warranty service $ 37 35 - $ 72 All consideration from contracts with customers is included in the amounts presented above. Contract Costs The Company recognizes the incremental costs of obtaining contracts as an expense when incurred if the amortization period of the assets that the Company otherwise would have recognized is one year or less. These costs are included in selling, general, and administrative expenses. The costs to obtain a contract are recorded immediately in the period when the revenue is recognized either upon shipment or installation. The costs to obtain a service contract are considered immaterial when spread over the life of the contract so the Company records the costs immediately upon billing. Concentrations Credit Risk Our financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash, cash equivalents, and trade receivables. We have cash investment policies which, among other things, limit investments to investment-grade securities. We perform ongoing credit evaluations of our customers, and the risk with respect to trade receivables is further mitigated by the fact that many of our customers are government institutions, large pharmaceutical and biotechnology companies, and academic laboratories. The following table illustrates the level of concentration as a percentage of total revenues during the three months and six months ended June 30, 2020 and 2019. For the Three Months Ended June 30, 2020 2019 Top Five Customers 71 % 47 % Federal Agencies 2 % 9 % For the Six Months Ended June 30, 2019 2019 Top Five Customers 70 % 55 % Federal Agencies 4 % 14 % The following table illustrates the level of concentration as a percentage of net accounts receivable balance as of June 30, 2020 and December 31, 2019. The Top Five Customers category may include federal agency receivable balances if applicable. June 30, 2020 December, 31, 2019 Top Five Customers 82 % 83 % Federal Agencies 5 % 17 % Product Supply CBM Industries (Taunton, MA) has recently become the manufacturer of the Barocycler® 2320EXT. CBM is ISO 13485:2003 and 9001:2008 Certified. CBM provides us with precision manufacturing services that include management support services to meet our specific application and operational requirements. Among the services provided by CBM to us are: ● CNC Machining ● Contract Assembly & Kitting ● Component and Subassembly Design ● Inventory Management ● ISO certification At this time, we believe that outsourcing the manufacturing of our new Barocycler® 2320EXT to CBM is the most cost-effective method for us to obtain and maintain ISO Certified, CE and CSA Marked instruments. CBM’s close proximity to our South Easton, MA facility is a significant asset enabling interactions between our Engineering, R&D, and Manufacturing groups and their counterparts at CBM. CBM was instrumental in helping PBI achieve CE Marking on our Barocycler 2320EXT, as announced on February 2, 2017. Although we currently manufacture and assemble the Barozyme HT48, Barocycler® HUB440, the SHREDDER SG3, and most of our consumables at our South Easton, MA facility, we plan to take advantage of outsourced manufacturing relationships such as that with CBM and outsource manufacturing of the entire Barocycler® product line, future instruments, and other products to CBM. Investment in Equity Securities As of June 30, 2020, we held 100,250 shares of common stock of Everest Investments Holdings S.A. (“Everest”), a Polish publicly traded company listed on the Warsaw Stock Exchange. We account for this investment in accordance with ASC 321 “Investments —Equity Securities.” Computation of Loss per Share Basic loss per share is computed by dividing loss available to common shareholders by the weighted average number of common shares outstanding. Diluted loss per share is computed by dividing loss available to common shareholders by the weighted average number of common shares outstanding plus additional common shares that would have been outstanding if dilutive potential common shares had been issued. For purposes of this calculation, convertible preferred stock, common stock dividends, and warrants and options to acquire common stock, are all considered common stock equivalents in periods in which they have a dilutive effect and are excluded from this calculation in periods in which these are anti-dilutive to our net loss. The following table illustrates our computation of loss per share for the three months and six months ended June 30, 2020 and 2019: For the Three Months Ended For the Six Months Ended June 30, June 30, 2020 2019 2020 2019 Numerator: Net loss $ (4,568,782 ) $ (2,766,842 ) $ (8,522,667 ) $ (4,822,015 ) Deemed dividend on beneficial conversion feature - (889,532 ) - (1,949,731 ) Preferred stock dividends (396,970 ) (420,489 ) (721,556 ) (776,099 ) Net loss applicable to common shareholders $ (4,965,752 ) $ (4,076,863 ) $ (9,244,223 ) $ (7,547,845 ) Denominator for basic and diluted loss per share: Weighted average common stock shares outstanding 2,914,659 1,837,913 2,765,132 1,780,881 Loss per common share – basic and diluted $ (1.70 ) $ (2.22 ) $ (3.34 ) $ (4.24 ) The following table presents securities that could potentially dilute basic loss per share in the future. For all periods presented, the potentially dilutive securities were not included in the computation of diluted loss per share because these securities would have been anti-dilutive to our net loss. The Series D Convertible Preferred Stock, Series G Convertible Preferred Stock, Series H and H2 Convertible Preferred Stock, Series J Convertible Preferred Stock, Series K Convertible Preferred Stock and Series AA Convertible Preferred Stock are presented below as if they were converted into common shares according to the conversion terms. As of June 30, 2020 2019 Stock options 1,392,370 347,070 Convertible debt 3,905,867 692,715 Common stock warrants 12,761,126 8,880,554 Convertible preferred stock: Series D Convertible Preferred Stock 25,000 25,000 Series G Convertible Preferred Stock 26,857 26,857 Series H Convertible Preferred Stock 33,334 33,334 Series H2 Convertible Preferred Stock 70,000 70,000 Series J Convertible Preferred Stock 115,267 115,267 Series K Convertible Preferred Stock 229,334 229,334 Series AA Convertible Preferred Stock 7,939,000 7,518,622 26,498,155 17,938,753 Accounting for Stock-Based Compensation Expense We maintain equity compensation plans under which incentive stock options and non-qualified stock options are granted to employees, independent members of our Board of Directors and outside consultants. We recognize stock-based compensation expense over the requisite service period using the Black-Scholes formula to estimate the fair value of the stock options on the date of grant. Determining Fair Value of Stock Option Grants Valuation and Amortization Method - The fair value of each option award is estimated on the date of grant using the Black-Scholes pricing model based on certain assumptions. The estimated fair value of employee stock options is amortized to expense using the straight-line method over the vesting period. Expected Term - The Company uses the simplified calculation of expected life, as the Company does not currently have sufficient historical exercise data on which to base an estimate of expected term. Using this method, the expected term is determined using the average of the vesting period and the contractual life of the stock options granted. Expected Volatility - Expected volatility is based on the Company’s historical stock volatility data over the expected term of the award. Risk-Free Interest Rate - The Company bases the risk-free interest rate used in the Black-Scholes valuation method on the implied yield currently available on U.S. Treasury zero-coupon issues with an equivalent remaining term. Forfeitures - The Company records stock-based compensation expense only for those awards that are expected to vest. The Company estimated a forfeiture rate of 5% for awards granted based on historical experience and future expectations of options vesting. The Company used this historical rate as our assumption in calculating future stock-based compensation expense. The Company recognized stock-based compensation expense of $65,341 and $362,182 for the three months ended June 30, 2020 and 2019, respectively. The Company recognized stock-based compensation expense of $307,110 and $607,574 for the six months ended June 30, 2020 and 2019, respectively. The following table summarizes the effect of this stock-based compensation expense within each of the line items of our costs and expenses within our Consolidated Statements of Operations: For the Three Months Ended For the Six Months Ended June 30, June 30, 2020 2019 2020 2019 Cost of sales $ 5,107 $ 12,082 $ 13,063 $ 20,398 Research and development 26,137 49,948 64,963 84,573 Selling and marketing 6,358 28,959 20,294 51,078 General and administrative 27,739 271,193 208,780 451,525 Total stock-based compensation expense $ 65,341 $ 362,182 $ 307,110 $ 607,574 Fair Value of Financial Instruments Due to their short maturities, the carrying amounts for cash and cash equivalents, accounts receivable, accounts payable, accrued expenses and debt approximate their fair value. Long-term liabilities include only deferred revenue with a carrying value that approximates fair value. Fair Value Measurements The Company follows the guidance of FASB ASC Topic 820, “ Fair Value Measurements and Disclosures The Company generally defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). The Company uses a three-tier fair value hierarchy, which classifies the inputs used in measuring fair values. These tiers include: Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring the Company to develop its own assumptions. A slight change in an unobservable input like volatility could have a significant impact on fair value measurement. Financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company has determined that its financial assets are classified within Level 1 in the fair value hierarchy. The development of the unobservable inputs for Level 3 fair value measurements and fair value calculations are the responsibility of the Company’s management. The following tables set forth the Company’s financial assets and liabilities that were accounted for at fair value on a recurring basis as of June 30, 2020: Fair value measurements at June 30, 2020 Quoted Significant (Level 2) Significant (Level 3) Equity Securities 362,905 362,905 - - Total Financial Assets $ 362,905 $ 362,905 $ - $ - The following tables set forth the Company’s financial assets and liabilities that were accounted for at fair value on a recurring basis as of December 31, 2019: Fair value measurements at December 31, 2019 Quoted Significant Significant Equity Securities 16,643 16,643 - - Total Financial Assets $ 16,643 $ 16,643 $ - $ -

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2020
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	4) Commitments and Contingencies Operating Leases The Company accounts for its leases under ASC 842. The Company has elected to apply the short-term lease exception to leases of one year or less. Consequently, as a result of adoption of ASC 842, we recognized an operating liability of $136,385 on our Medford lease with a corresponding Right-Of-Use (“ROU”) asset of the same amount based on present value of the minimum rental payments of the lease. As of June 30, 2020 the Company carries a ROU asset and operating lease liability of $40,659. Our corporate office is currently located at 14 Norfolk Avenue, South Easton, Massachusetts 02375. We are currently paying $6,950 per month, on a lease extension, signed on December 31, 2019, that expires December 31, 2020, for our corporate office. We expanded our space to include offices, warehouse and a loading dock on the first floor starting May 1, 2017 with a monthly rent increase already reflected in the current payments. We extended our lease for our space in Medford, MA to December 30, 2020. The lease requires monthly payments of $7,130 subject to annual cost of living increases. The lease shall be automatically extended for an additional three years unless either party terminates at least six months prior to the expiration of the current lease term. Following is a schedule by years of future minimum rental payments required under operating leases with initial or remaining non-cancelable lease terms as of June 30, 2020: 2020 $ 84,480 Thereafter - Total Minimum Payments Required $ 84,480

Loan Receivable

Loan Receivable	6 Months Ended
	Jun. 30, 2020
Loan Receivable
Loan Receivable	5) Loan Receivable In the six months ended June 30, 2020, the Company issued two loans for $575,000 to its pending merger partner, Cannaworx who agreed to repay the loans directly to the lender, on the Company’s behalf. The Cannaworx loans have one-year terms and interest (12% for a $325,000 note and 18% for a $250,000 note) is only payable upon an event of default. Cannaworx loans receivable are carried on the Company’s balance sheet net of a $43,750 debt discount.

Convertible Debt and Other Debt

Convertible Debt and Other Debt	6 Months Ended
	Jun. 30, 2020
Debt Disclosure [Abstract]
Convertible Debt and Other Debt	6) Convertible Debt and Other Debt Convertible Debt On various dates during the six months ended June 30, 2020, the Company issued convertible notes for net proceeds of approximately $4.4 million which contained varied terms and conditions as follows: a) 12 month maturity date; b) interest rate of 10%; c) convertible to the Company’s common stock at issuance at a fixed rate of $2.50. These notes were issued with warrants to purchase common stock that were fair valued at issuance date. The aggregate relative fair value of the warrants issued with the notes $2,705,996 was recorded as a debt discount to be amortized over the term of the notes. We then computed the effective conversion price of the notes, and recorded a $982,097 beneficial conversion feature as a debt discount to be amortized over the term of the notes. We also evaluated the convertible notes for derivative liability treatment and determined that the notes did not quality for derivative accounting treatment at June 30, 2020. The specific terms of the convertible notes and outstanding balances as of June 30, 2020 are listed in the tables below. Lender Inception Date Term Loan Amount Outstanding balance with OID Original Issue Discount (OID) Interest Rate Conversion Price Deferred Finance Fees Discount for conversion feature and warrants/shares Vision #1 February 15, 2018 (2)(3)(4) 6 months $ 100,000 $ 115,000 $ - 5 % 2.50 $ 9,000 $ 17,738 Auctus May 17, 2018 (2) 12 months $ 380,000 $ 166,703 $ 15,200 8 % 2.50 $ 15,200 $ 332,407 Carlino June 8, 2018 (1)(4) 6 months $ 50,000 $ 50,000 $ 2,500 2 % 7.50 $ 2,500 $ 3,271 GS June 16, 2018 (2) 9 months $ 130,000 $ 79,000 $ - 5 % 2.50 $ - $ - GS June 16, 2018 (2) 6 months $ 110,000 $ 79,000 $ - 5 % 2.50 $ - $ - Vision #4 June 26, 2018 (1)(2)(3)(4) 3 months $ 150,000 $ 86,250 $ - 5 % 2.50 $ - $ 30,862 Vision #5 July 17, 2018 (1) (2)(3)(4) 3 months $ 100,000 $ 105,000 $ 15,000 5 % 2.50 $ - $ 52,897 BHP July 19, 2018 (2) 12 months $ 184,685 $ 150,000 $ 34,685 10 % 2.50 $ - $ - Casale October 19, 2018 (1) 6 months $ 100,000 $ 100,000 $ - 5 % 7.50 $ - $ - Vision #6 November 13, 2018 (1) (2)(3)(4) 6 months $ 200,000 $ 220,000 $ - 5 % 2.50 $ - $ 168,634 James Gathard January 3, 2019 (1)(4) 6 months $ 50,000 $ 50,000 $ 2,500 24 % 7.50 $ 2,500 $ - Eagle Equities LLC February 21, 2019 (2) 12 months $ 215,000 $ 215,000 $ - 4 % 2.50 $ 15,000 $ 107,709 Crossover February 22, 2019 (2) 9 months $ 115,563 $ 115,562 $ 8,063 7 % 2.50 $ 2,500 $ - Casale March 18, 2019 (1) 6 months $ 100,000 $ 100,000 $ - 4 % 7.50 $ - $ 10,762 Auctus June 4, 2019 (2) 9 months $ 500,000 $ 302,484 $ - 8 % 2.50 $ 40,500 $ 70,631 LG Capital April 30, 2019 (2) 12 months $ 105,000 $ 80,000 $ - 4 % 2.50 $ 5,000 $ 3,286 LG Capital June 19, 2019 (2) 12 months $ 105,000 $ 105,000 $ - 4 % 2.50 $ 5,000 $ 2,646 Morningview Financial April 9, 2019 (2) 12 months $ 118,800 $ 88,800 $ 8,800 4 % 2.50 $ 3,000 $ - Vision #9 May 20, 2019 (1) (2)(4) 3 months $ 100,000 $ 100,000 $ - 5 % 2.50 $ - $ 13,439 Vision #10 June 7, 2019 (1) (2)(4) 6 months $ 125,000 $ 125,000 $ - 5 % 7.50 $ - $ 18,254 Eagle Equities LLC July 1, 2019 (2) 12 months $ 107,500 $ 107,500 $ - 4 % 2.50 $ 7,500 $ 85,791 C and B Holdings NY July 29, 2019 (2) 6 months $ 250,000 $ 250,000 $ - 4 % 2.50 $ - $ 36,835 LG Capital July 19, 2019 (2) 12 months $ 115,000 $ 115,000 $ - 4 % 2.50 $ 5,750 $ 15,460 Odyssey Capital July 19, 2019 (2) 12 months $ 130,000 $ 130,000 $ - 6 % 2.50 $ 6,500 $ - Morningview Financial August 6, 2019 (2) 12 months $ 108,000 $ 108,000 $ - 4 % 2.50 $ 11,000 $ - Sheila Bloom-Rosenberg August 14, 2019 (1)(4) 6 months $ 50,000 $ 50,000 $ - 2 % 7.50 $ - $ - LG Capital September 27, 2019 (2) 12 months $ 78,750 $ 78,750 $ - 4 % 2.50 $ 3,750 $ 13,759 LG Capital October 24, 2019 (2) 12 months $ 78,750 $ 78,750 $ - 4 % 2.50 $ 3,750 $ - GW October 25, 2019 12 months $ 105,000 $ 105,000 $ - 8 % 2.50 $ 5,000 $ - Odyssey Capital November 1, 2019 (2) 12 months $ 270,000 $ 270,000 $ - 6 % 2.50 $ 13,500 $ - C&B Holdings October 8, 2019 6 months $ 100,000 $ 100,000 $ - 4 % 7.50 $ - $ 5,725 Clay 11/15/2019 Loan 1 November 15, 2019 12 months $ 385,000 $ 385,000 $ 35,000 10 % 2.50 $ 35,000 $ 90,917 Clay 12/4/2019 Loan 2 December 4, 2019 12 months $ 495,000 $ 495,000 $ 45,000 10 % 2.50 $ 45,000 $ 56,387 Clay 12/20/2019 Loan 4 December 20, 2019 12 months $ 275,000 $ 275,000 $ 25,000 10 % 2.50 $ 25,000 $ 40,601 Clay 1/2/2020 Loan January 2, 2020 12 months $ 330,000 $ 330,000 $ 30,000 10 % 2.50 $ 30,000 $ 91,606 Clay 1/24/2020 Loan January 24, 2020 12 months $ 247,500 $ 247,500 $ 22,500 10 % 2.50 $ 22,500 $ 89,707 Clay 1/29/2020 Loan January 29, 2020 12 months $ 363,000 $ 363,000 $ 33,000 10 % 2.50 $ 33,000 $ 297,000 Clay 2/12/20 Loan February 12, 2020 12 months $ 275,000 $ 275,000 $ 25,000 10 % 2.50 $ 25,000 $ 225,000 Clay 2/21/20 Loan February 19, 2020 12 months $ 165,000 $ 165,000 $ 15,000 10 % 2.50 $ 15,000 $ 135,000 Clay 3/11/20 March 11, 2020 12 months $ 330,000 $ 330,000 $ 30,000 10 % 2.50 $ 30,000 $ 232,810 Clay 3/13/20 March 13, 2020 12 months $ 165,000 $ 165,000 $ 15,000 10 % 2.50 $ 15,000 $ 60,705 Clay 3/26/20 Loan March 26, 2020 12 months $ 111,100 $ 111,100 $ 10,100 10 % 2.50 $ 10,100 $ 90,900 Clay 4/8/20 Loan April 8, 2020 12 months $ 276,100 $ 276,100 $ 25,100 10 % 2.50 $ 25,000 $ 221,654 Clay 4/17/20 Loan April 17, 2020 12 months $ 143,750 $ 143,750 $ 18,750 10 % 2.50 $ - $ 96,208 Clay 4/22/20 Loan April 30, 2020 12 months $ 546,250 $ 546,250 $ 71,250 10 % 2.50 $ 47,500 $ 427,500 Clay 5/4/20 Loan May 7, 2020 12 months $ 460,000 $ 460,000 $ 60,000 10 % 2.50 $ 40,000 $ 360,000 Clay 5/11/20 Loan May 18, 2020 12 months $ 546,250 $ 546,250 $ 71,250 10 % 2.50 $ 35,500 $ 439,500 Clay 5/20/20 Loan June 2, 2020 12 months $ 902,750 $ 902,750 $ 117,750 10 % 2.50 $ 58,900 $ 708,500 Geer 6/1/20 Loan May 29, 2020 12 months $ 110,000 $ 110,000 $ 10,000 10 % 2.50 $ - $ - Clay 6/12/20 Loan June 12, 2020 12 months $ 57,500 $ 57,500 $ 7,500 10 % 2.50 $ 5,000 $ 45,000 Clay 6/22/20 Loan June 22, 2020 12 months $ 138,000 $ 138,000 $ 18,000 10 % 2.50 $ 12,000 $ 108,000 $ 10,147,999 $ 771,948 $ 666,450 $ 4,807,101 (1) The Note is past due. The Company and the lender are negotiating in good faith to extend the loan. (2) As of June 30, 2020 lender entered into a Standstill and Forbearance agreement (as described below). Loan is convertible at $2.50 until the expiration of the agreement. (3) Interest was capitalized and added to outstanding principal. (4) During the six months ended June 30, 2020 the Company entered into Rate Modification Agreements with these lenders. In these agreements five lenders agreed to reduce their interest rate and were granted the right to convert loans using a variable conversion price if other variable rate lenders converted at a variable rate. For the six months ended June 30, 2020, the Company recognized amortization expense related to the debt discounts indicated above of $1,397,121. The unamortized debt discounts as of June 30, 2020 related to the convertible debentures and other convertible notes amounted to $3,923,549. Standstill and Forbearance Agreements On December 13, 2019, the Company entered into Standstill and Forbearance Agreements with lenders who hold convertible promissory notes with a total principal of $2,267,066. Pursuant to the Standstill and Forbearance Agreements, the lenders agreed to not convert any portion of their notes into shares of common stock at a variable rate until either January 30 th st th st On January 31, 2020 and again on March 3, 2020, April 6, 2020, April 30, 2020, May 15, 2020, May 31, 2020 and June 15, 2020 the Company extended these Standstill and Forbearance Agreements until June 30, 2020. For the three months ended June 30, 2020, the Company incurred fees of approximately $1,660,000 to extend the agreements. Convertible Loan Modifications and Extinguishments We refinanced certain convertible loans during the six months ended June 30, 2020 at substantially the same terms for extensions ranging over a period of three to six months. We amortized any remaining unamortized debt discount as of the modification date over the remaining, extended term of the new loans. We applied ASC 470 of modification accounting to the debt instruments which were modified during the quarter or those settled with new notes issued concurrently for the same amounts but different maturity dates. The terms such as the interest rate, prepayment penalties, and default rates will be the same over the new extensions. According to ASC 470, an exchange of debt instruments between or a modification of a debt instrument by a debtor and a creditor in a nontroubled debt situation is deemed to have been accomplished with debt instruments that are substantially different if the present value of the cash flows under the terms of the new debt instrument is at least 10 percent different from the present value of the remaining cash flows under the terms of the original instrument. If the terms of a debt instrument are changed or modified and the cash flow effect on a present value basis is less than 10 percent, the debt instruments are not considered to be substantially different and will be accounted for as modifications. The cash flows of new debt exceeded 10% of the remaining cash flows of the original debt on several loans. During the six months ended June 30, 2020 we recorded losses on extinguishment of liabilities of approximately $2.8 million by calculating the difference of the fair value of the new debt and the carrying value of the old debt. The reported loss on extinguishment of liabilities includes $977,622 of non-cash expenses for warrants issued and writeoff, of any unamortized discount at the date of modification. The following table provides a summary of the changes in convertible debt, net of unamortized discounts, during 2020: 2020 Balance at January 1, $ 6,121,338 Issuance of convertible debt, face value 5,435,950 Deferred financing cost (1,013,350 ) Beneficial conversion feature on convertible note (982,097 ) Debt discount from warrants issued with debt (2,705,996 ) Payments (1,257,250 ) Conversion of debt into equity (771,266 ) Accretion of interest and amortization of debt discount to interest expense 1,397,121 Balance at June 30, 6,224,450 Less: current portion 6,224,450 Convertible debt, long-term portion $ – Other Notes On September 9, 2019 and February 28, 2020 we received a total of $966,500 unsecured non-convertible loans from a private investor with a one-month term. During the six months ended June 30, 2020, the Company received net proceeds of $463,500, issued 150,000 warrants to purchase common stock (five-year term and $3.50 exercise price) and repaid $275,000. The relative fair value of $185,660 of the warrants issued with the note was recorded as a debt discount to be amortized over the term of the notes. As of June 30, 2020 the Company owes $691,500 on these notes which are past due. The Company and the investor are negotiating in good faith to extend the loans. On October 1, 2019, the Company and the holder of the $170,000 non-convertible loan issued in May 2017 agreed to extend the term of the loan to December 31, 2019. The Company agreed to issue 1,200 shares of its common stock per month while the note remains outstanding. The note will continue to earn 10% annual interest. The loan is currently past due and the Company and the investor are negotiating in good faith to extend the loan. On October 11, 2019 we received a non-convertible loan with a one month term and a 2% interest charge for $25,000 from a private investor. The loan is past due and the Company and the investor are negotiating in good faith to extend the loan. For the six months ended June 30, 2020, the Company recognized amortization expense related to debt discounts attributable to other notes of $353,790. Merchant Agreements We have signed various Merchant Agreements which are secured by second position rights to all customer receipts until the loan has been repaid in full and subject to interest rates of 6% - 76%. As illustrated in the following table, under the terms of these agreements, we received the disclosed Purchase Price and agreed to repay the disclosed Purchase Amount, which is collected by the Merchant lenders at the disclosed Daily Payment Rate. The following table shows our Merchant Agreements as of June 30, 2020: Inception Date Purchase Price Purchased Amount Outstanding Balance Daily Payment Rate Deferred August 5, 2019 $ 600,000 $ 816,000 $ 174,943 $ 4,533 $ 6,000 August 19, 2019 350,000 479,500 245,355 2,664 3,000 August 23, 2019 175,000 239,750 87,192 1,410 1,750 September 19, 2019 275,000 384,275 183,348 2,138 5,000 $ 1,400,000 $ 1,919,525 $ 690,838 $ 10,745 $ 15,750 The following table shows our Merchant Agreements as of December 31, 2019: Inception Date Purchase Price Purchased Amount Outstanding Balance Daily Payment Rate Deferred Finance Fees August 5, 2019 $ 600,000 $ 816,000 $ 421,024 4,533 $ 6,000 August 19, 2019 350,000 479,500 272,315 2,664 3,000 August 23, 2019 175,000 239,750 132,284 1,410 1,750 September 19, 2019 275,000 384,275 256,812 2,138 5,000 $ 1,400,000 $ 1,919,525 $ 1,082,435 $ 10,745 $ 15,750 We have accounted for the Merchant Agreements as loans under ASC 860 because while we provided rights to current and future receipts, we still had control over the receipts. The difference between the Purchase Amount and the Purchase Price is imputed interest that is recorded as interest expense when paid each day. On November 15, 2019 the Company and its Merchant lenders agreed to a temporary reduction in the Daily Payment Rate. Subsequently, on January 31, 2020, March 2, 2020 and April 6, 2020 the Company and its Merchant lenders agreed to extend the term of the reduction of its Daily Payment Rate, ultimately to April 30, 2020. The Company issued 495,000 warrants to lenders (valued at $969,745) as compensation for these agreements. The warrants have a three year life and a $3.50 exercise Price. During the six months ended June 30, 2020, $152,552 of interest was capitalized into principal (and recorded as interest expense). The Company’s Chief Executive Officer is personally guaranteeing $690,838 of loans outstanding as of June 30, 2020 under our Merchant Agreements. Related Party Notes In June 2018, we received a non-convertible loan of $15,000 from a private investor. The loan includes a one-year term and 15% guaranteed interest. This loan remains outstanding at June 30, 2020 and is currently past due. As of June 30, 2020 we also hold $75,000 of short-term non-convertible loans from related parties. These notes bear interest ranging from 0% to 15% interest and are due upon demand. Long term debt During the six months ended June 30, 2020, the Company borrowed $527,039 through COVID-19 programs that were sponsored by the United States and administered by the Small Business Administration (the “SBA”). The most notable programs were the Payroll Protection Program (or “PPP”) and the Economic Injury Disaster Loan program (or “EIDL”). The Company’s PPP loan, $377,039, has a two- year term and bears interest at 1% per annum. Under the PPP, the Company can be granted forgiveness for all or a portion of these loans based on the Company’s spending on payroll, mortgage interest, rent and utilities. The Company’s EIDL loan, $150,000, accrues interest at 3.75% and requires monthly payments of $731 for principal and interest beginning in June 2021. The balance of the principal will be due in 30 years. In connection with the EIDL loan the Company entered into a security agreement with the SBA, whereby the Company granted the SBA a security interest in all of the Company’s right, title and interest in all of the Company’s assets.

Stockholders' Deficit

Stockholders' Deficit	6 Months Ended
	Jun. 30, 2020
Equity [Abstract]
Stockholders' Deficit	7) Stockholders’ Deficit Preferred Stock We are authorized to issue 1,000,000 shares of preferred stock with a par value of $0.01. Of the 1,000,000 shares of preferred stock: 1) 20,000 shares have been designated as Series A Junior Participating Preferred Stock (“ Junior A 2) 313,960 shares have been designated as Series A Convertible Preferred Stock (“ Series A 3) 279,256 shares have been designated as Series B Convertible Preferred Stock (“ Series B 4) 88,098 shares have been designated as Series C Convertible Preferred Stock (“ Series C 5) 850 shares have been designated as Series D Convertible Preferred Stock (“ Series D 6) 500 shares have been designated as Series E Convertible Preferred Stock (“Series E”) 7) 240,000 shares have been designated as Series G Convertible Preferred Stock (“ Series G 8) 10,000 shares have been designated as Series H Convertible Preferred Stock (“ Series H 9) 21 shares have been designated as Series H2 Convertible Preferred Stock (“ Series H2 10) 6,250 shares have been designated as Series J Convertible Preferred Stock (“ Series J 11) 15,000 shares have been designated as Series K Convertible Preferred Stock (“ Series K 12) 10,000 shares have been designated as Series AA Convertible Preferred Stock (“ Series AA As of June 30, 2020, there were no shares of Junior A, and Series A, B, C and E issued and outstanding. See our Annual Report on Form 10-K for the year ended December 31, 2019 for the pertinent disclosures of preferred stock. Stock Options and Warrants At the Company’s December 12, 2013 Special Meeting, the shareholders approved the 2013 Equity Incentive Plan (the “2013 Plan”) pursuant to which 3,000,000 shares of our common stock were reserved for issuance upon exercise of stock options or other equity awards. Under the 2013 Plan, we may award stock options, shares of common stock, and other equity interests in the Company to employees, officers, directors, consultants, and advisors, and to any other persons the Board of Directors deems appropriate. As of June 30, 2020, options to acquire 1,392,370 shares were outstanding under the Plan. On November 29, 2015 the Company’s Board of Directors adopted the 2015 Nonqualified Stock Option Plan (the “2015 Plan”) pursuant to which 5,000,000 shares of our common stock were reserved for issuance upon exercise of non-qualified stock options. Under the 2015 Plan, we may award non-qualified stock options in the Company to employees, officers, directors, consultants, and advisors, and to any other persons the Board of Directors deems appropriate. As of June 30, 2020, total unrecognized compensation cost related to the unvested stock-based awards was $589,652, which is expected to be recognized over weighted average period of 1.61 years. The aggregate intrinsic value associated with the options outstanding and exercisable and the aggregate intrinsic value associated with the warrants outstanding and exercisable as of June 30, 2020, based on the June 30, 2020 closing stock price of $2.30, was $712,250. The following table summarizes information concerning options and warrants outstanding and exercisable: Stock Options Warrants Weighted Weighted Average Average Shares price per share Shares price per share Shares Total Balance outstanding, December 31, 2019 1,396,302 $ 0.71 9,893,034 $ 3.52 11,289,336 10,148,543 Granted - - 2,907,870 3.50 2,907,870 Exercised - - - - - Expired - - (39,778 ) $ 8.40 (39,778 ) Forfeited (3,932 ) 0.69 - - (3,932 ) Balance outstanding, June 30, 2020 1,392,370 $ 0.69 12,761,126 $ 3.50 14,153,496 13,203,517 As of June 30, 2020, the 1,392,370 stock options outstanding have a $0.69 Exercise Price and 9.20 weighted average remaining term. Of these options, 442,391 are currently exercisable. Common Stock and Warrant Issuances During the six months ended June 30, 2020, we issued to Series AA holders 64,388 shares of common stock for dividends totaling of $176,748 issued in stock in lieu of cash. During this period the Company also issued 593,277 shares of restricted common stock at a fair value of $1,693,251 to accredited investors and consultants. 420,746 of the shares with a fair value of $1,317,649 were issued for conversions of debt principal and interest; 81,031 of the shares with a fair value of $159,784 were issued for debt extensions and interest payments; 66,500 shares with a fair value of $127,855 were issued to settle an accrued liability; and 25,000 shares with a fair value of $87,963 were issued for services rendered. During this period, the Company also issued 2,412,870 warrants to acquire common stock at a fair value of $2,958,693 in conjunction with the signing of new convertible loans and 495,000 warrants to acquire common stock at a fair value of $969,745 to lenders for debt extension. During the six months ended June 30, 2019, we issued to Series AA holders 42,456 shares of common stock for dividends totaling of $105,941 issued in stock in lieu of cash. During this period the Company also issued 205,432 shares of restricted common stock at a fair value of $641,211 to accredited investors. 65,377 of the shares with a fair value of $156,322 were issued to existing holders of convertible loans who agreed to extend the terms of the loans for another six months; 47,599 shares with a fair value of $156,322 were issued in conjunction with the signing of new convertible loans; and 50,000 shares with a fair value of $168,000 were issued for services rendered.

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2020
Subsequent Events [Abstract]
Subsequent Events	8) Subsequent Events On July 6, 2020, the Company signed an amendment to its binding letter of intent to acquire Cannaworx, Inc. (USA), extending the completion deadline to July 31,2020 with two 30-day automatic extensions. The planned acquisition remains subject to certain closing conditions, including completion of all due diligence and acquisition financing. From July 1, 2020 through August 12, 2020 the Company issued loans convertible into common stock at $2.50/share for $1.7 million. The loans carry 10% interest rates and one-year terms. To secure these loans, the Company issued 22,500 shares of common stock and warrants exercisable into 595,700 common shares (five-year life and a $3.50 exercise price). During this period, the Company also paid off five convertible loans totaling $702,800. The loans were issued July 19, 2018, April 9, 2019, July 29, 2019, August 6, 2019 and October 8, 2019. To retire these loans Company paid $472,371 in cash and issued 248,898 shares of common stock and 103,469 warrants to acquire common stock (three-year life and $3.50 exercise price) in full payment of principal, interest and fees. In this period the Company also issued 24,000 shares of common stock in partial settlement of $54,397 of principal and fees on a loan issued February 22, 2019. From July 1, 2020 to August 12, 2020 the Company entered into Standstill and Forbearance Agreements with lenders who hold convertible notes with a principal balance of approximately $1.97 million. Lenders have agreed with the Company not to convert any portion of their notes at a variable rate until August 31, 2020. On July 7, 2020, the Company and its Merchant lenders agreed to a final resolution of their arrangements. In this agreement, Company paid $385,388, issued 112,885 shares of common stock and 112,885 warrants to the Merchant lenders. The warrants have a three-year life and a $3.50 exercise price.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2020
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The unaudited interim financial statements of Pressure BioSciences, Inc. and its consolidated subsidiaries (collectively, the “Company”) included herein have been prepared by the Company in accordance with the instructions to Form 10-Q and the rules and regulations of the U.S. Securities and Exchange Commission. Under these rules and regulations, some information and footnote disclosures normally included in financial statements prepared under accounting principles generally accepted in the United States of America have been shortened or omitted. Management believes that all adjustments necessary for a fair statement of the financial position and the results of operations for the periods shown have been made. All adjustments are normal and recurring. These financial statements should be read together with the Company’s audited financial statements included in its Form 10-K for the fiscal year ended December 31, 2019.
Use of Estimates	Use of Estimates The Company’s consolidated financial statements and accompanying notes are prepared in accordance with accounting principles generally accepted in the United States of America, which require the use of estimates, judgements and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the periods presented. Global concerns about the COVID-19 pandemic have adversely affected, and we expect will continue to adversely affect, our business, financial condition and results of operations including the estimates and assumptions made by management. Significant estimates and assumptions include valuations of share-based awards, investments in equity securities and intangible asset impairment. Actual results could differ from the estimates, and such differences may be material to the Company’s consolidated financial statements.
Principles of Consolidation	Principles of Consolidation The consolidated financial statements include the accounts of Pressure BioSciences, Inc., and its wholly-owned subsidiary PBI BioSeq, Inc. All intercompany accounts and transactions have been eliminated in consolidation.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In June 2016, the FASB issued ASU 2016-13, Measurement of Credit Losses on Financial Instruments. The standard is effective for the Company for interim and annual periods beginning after December 15, 2022. The Company is evaluating the impact of this standard on its Consolidated Financial Statements. In December 2019, the FASB, issued ASU 2019-12, Simplifying the Accounting for Income Taxes. The standard is effective for the Company for interim and annual periods beginning after December 15, 2020 for the Company and for annual periods beginning after December 15, 2021 and interim periods beginning after December 15, 2022. The Company is evaluating the impact of this standard on its Consolidated Financial Statements.
Revenue Recognition	Revenue Recognition We recognize revenue in accordance with FASB ASC 606, Revenue from Contracts with Customers, ASC 340-40, Other Assets and Deferred Costs—Contracts with Customers We identify a performance obligation as distinct if both the following criteria are true: the customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer and the entity’s promise to transfer the good or service to the customer is separately identifiable from other promises in the contract. Determining the standalone selling price (“SSP”) and allocation of consideration from a contract to the individual performance obligations, and the appropriate timing of revenue recognition, is the result of significant qualitative and quantitative judgments. Management considers a variety of factors such as historical sales, usage rates, costs, and expected margin, which may vary over time depending upon the unique facts and circumstances related to each performance obligation in making these estimates. While changes in the allocation of the SSP between performance obligations will not affect the amount of total revenue recognized for a particular contract, any material changes could impact the timing of revenue recognition, which would have a material effect on our financial position and result of operations. This is because the contract consideration is allocated to each performance obligation, delivered or undelivered, at the inception of the contract based on the SSP of each distinct performance obligation. Taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction, that are collected by the Company from a customer, are excluded from revenue. Shipping and handling costs associated with outbound freight after control over a product has transferred to a customer are accounted for as a fulfillment cost and are in included in cost of revenues as consistent with treatment in prior periods. Our current Barocycler® instruments require a basic level of instrumentation expertise to set-up for initial operation. To support a favorable first experience for our customers, upon customer request, and for an additional fee, will send a highly trained technical representative to the customer site to install Barocycler®s that we sell, lease, or rent through our domestic sales force. The installation process includes uncrating and setting up the instrument, followed by introductory user training. Our sales arrangements do not provide our customers with a right of return. Any shipping costs billed to customers are recognized as revenue. The majority of our instrument and consumable contracts contain pricing that is based on the market price for the product at the time of delivery. Our obligations to deliver product volumes are typically satisfied and revenue is recognized when control of the product transfers to our customers. Concurrent with the transfer of control, we typically receive the right to payment for the shipped product and the customer has significant risks and rewards of ownership of the product. Payment terms require customers to pay shortly after delivery and do not contain significant financing components. We apply ASC 845, “Accounting for Non-Monetary Transactions”, to account for products and services sold through non-cash transactions based on the fair values of the products and services involved, where such values can be determined. Non-cash exchanges would require revenue to be recognized at recorded cost or carrying value of the assets or services sold if any of the following conditions apply: a) The fair value of the asset or service involved is not determinable. b) The transaction is an exchange of a product or property held for sale in the ordinary course of business for a product or property to be sold in the same line of business to facilitate sales to customers other than the parties to the exchange. c) The transaction lacks commercial substance. We currently record revenue for its non-cash transactions at recorded cost or carrying value of the assets or services sold. In accordance with FASB ASC 842, Leases We record revenue over the life of the lease term and we record depreciation expense on a straight-line basis over the thirty-six-month estimated useful life of the Barocycler® instrument. The depreciation expense associated with assets under lease agreement is included in the “Cost of PCT products and services” line item in our accompanying consolidated statements of operations. Many of our lease and rental agreements allow the lessee to purchase the instrument at any point during the term of the agreement with partial or full credit for payments previously made. We pay all maintenance costs associated with the instrument during the term of the leases. Revenue from government grants is recorded when expenses are incurred under the grant in accordance with the terms of the grant award. Deferred revenue represents amounts received from grants and service contracts for which the related revenues have not been recognized because one or more of the revenue recognition criteria have not been met. Revenue from service contracts is recorded ratably over the length of the contract. Disaggregation of revenue In the following table, revenue is disaggregated by primary geographical market, major product line, and timing of revenue recognition. In thousands of US dollars ($) Three Months Ended Six Months Ended Primary geographical markets 2020 2019 2020 2019 North America $ 162 $ 368 $ 307 $ 592 Europe 3 54 4 94 Asia 103 97 211 343 $ 268 $ 519 $ 522 $ 1,029 Three Months Ended Six Months Ended Major products/services lines 2020 2019 2020 2019 Hardware $ 122 $ 212 $ 217 $ 352 Consumables 51 91 107 153 Contract research services 34 111 44 349 Sample preparation accessories 33 35 58 35 Technical support/extended service contracts 17 28 36 67 Shipping and handling 6 14 15 19 Other 5 28 45 54 $ 268 $ 519 $ 522 $ 1,029 Three Months Ended Six Months Ended Timing of revenue recognition 2020 2019 2020 2019 Products transferred at a point in time $ 217 $ 506 $ 442 $ 1,007 Services transferred over time 51 13 80 22 $ 268 $ 519 $ 522 $ 1,029 Contract balances In thousands of US dollars ($) June 30, 2020 December 31, 2019 Receivables, which are included in ‘Accounts Receivable’ $ 121 $ 229 Contract liabilities (deferred revenue) 72 41 Transaction price allocated to the remaining performance obligations The following table includes estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) at the end of the reporting period. In thousands of US dollars ($) 2020 2021 2022 Total Extended warranty service $ 37 35 - $ 72 All consideration from contracts with customers is included in the amounts presented above. Contract Costs The Company recognizes the incremental costs of obtaining contracts as an expense when incurred if the amortization period of the assets that the Company otherwise would have recognized is one year or less. These costs are included in selling, general, and administrative expenses. The costs to obtain a contract are recorded immediately in the period when the revenue is recognized either upon shipment or installation. The costs to obtain a service contract are considered immaterial when spread over the life of the contract so the Company records the costs immediately upon billing.
Concentrations	Concentrations Credit Risk Our financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash, cash equivalents, and trade receivables. We have cash investment policies which, among other things, limit investments to investment-grade securities. We perform ongoing credit evaluations of our customers, and the risk with respect to trade receivables is further mitigated by the fact that many of our customers are government institutions, large pharmaceutical and biotechnology companies, and academic laboratories. The following table illustrates the level of concentration as a percentage of total revenues during the three months and six months ended June 30, 2020 and 2019. For the Three Months Ended June 30, 2020 2019 Top Five Customers 71 % 47 % Federal Agencies 2 % 9 % For the Six Months Ended June 30, 2019 2019 Top Five Customers 70 % 55 % Federal Agencies 4 % 14 % The following table illustrates the level of concentration as a percentage of net accounts receivable balance as of June 30, 2020 and December 31, 2019. The Top Five Customers category may include federal agency receivable balances if applicable. June 30, 2020 December, 31, 2019 Top Five Customers 82 % 83 % Federal Agencies 5 % 17 %
Product Supply	Product Supply CBM Industries (Taunton, MA) has recently become the manufacturer of the Barocycler® 2320EXT. CBM is ISO 13485:2003 and 9001:2008 Certified. CBM provides us with precision manufacturing services that include management support services to meet our specific application and operational requirements. Among the services provided by CBM to us are: ● CNC Machining ● Contract Assembly & Kitting ● Component and Subassembly Design ● Inventory Management ● ISO certification At this time, we believe that outsourcing the manufacturing of our new Barocycler® 2320EXT to CBM is the most cost-effective method for us to obtain and maintain ISO Certified, CE and CSA Marked instruments. CBM’s close proximity to our South Easton, MA facility is a significant asset enabling interactions between our Engineering, R&D, and Manufacturing groups and their counterparts at CBM. CBM was instrumental in helping PBI achieve CE Marking on our Barocycler 2320EXT, as announced on February 2, 2017. Although we currently manufacture and assemble the Barozyme HT48, Barocycler® HUB440, the SHREDDER SG3, and most of our consumables at our South Easton, MA facility, we plan to take advantage of outsourced manufacturing relationships such as that with CBM and outsource manufacturing of the entire Barocycler® product line, future instruments, and other products to CBM.
Investment in Equity Securities	Investment in Equity Securities As of June 30, 2020, we held 100,250 shares of common stock of Everest Investments Holdings S.A. (“Everest”), a Polish publicly traded company listed on the Warsaw Stock Exchange. We account for this investment in accordance with ASC 321 “Investments —Equity Securities.”
Computation of Loss Per Share	Computation of Loss per Share Basic loss per share is computed by dividing loss available to common shareholders by the weighted average number of common shares outstanding. Diluted loss per share is computed by dividing loss available to common shareholders by the weighted average number of common shares outstanding plus additional common shares that would have been outstanding if dilutive potential common shares had been issued. For purposes of this calculation, convertible preferred stock, common stock dividends, and warrants and options to acquire common stock, are all considered common stock equivalents in periods in which they have a dilutive effect and are excluded from this calculation in periods in which these are anti-dilutive to our net loss. The following table illustrates our computation of loss per share for the three months and six months ended June 30, 2020 and 2019: For the Three Months Ended For the Six Months Ended June 30, June 30, 2020 2019 2020 2019 Numerator: Net loss $ (4,568,782 ) $ (2,766,842 ) $ (8,522,667 ) $ (4,822,015 ) Deemed dividend on beneficial conversion feature - (889,532 ) - (1,949,731 ) Preferred stock dividends (396,970 ) (420,489 ) (721,556 ) (776,099 ) Net loss applicable to common shareholders $ (4,965,752 ) $ (4,076,863 ) $ (9,244,223 ) $ (7,547,845 ) Denominator for basic and diluted loss per share: Weighted average common stock shares outstanding 2,914,659 1,837,913 2,765,132 1,780,881 Loss per common share – basic and diluted $ (1.70 ) $ (2.22 ) $ (3.34 ) $ (4.24 ) The following table presents securities that could potentially dilute basic loss per share in the future. For all periods presented, the potentially dilutive securities were not included in the computation of diluted loss per share because these securities would have been anti-dilutive to our net loss. The Series D Convertible Preferred Stock, Series G Convertible Preferred Stock, Series H and H2 Convertible Preferred Stock, Series J Convertible Preferred Stock, Series K Convertible Preferred Stock and Series AA Convertible Preferred Stock are presented below as if they were converted into common shares according to the conversion terms. As of June 30, 2020 2019 Stock options 1,392,370 347,070 Convertible debt 3,905,867 692,715 Common stock warrants 12,761,126 8,880,554 Convertible preferred stock: Series D Convertible Preferred Stock 25,000 25,000 Series G Convertible Preferred Stock 26,857 26,857 Series H Convertible Preferred Stock 33,334 33,334 Series H2 Convertible Preferred Stock 70,000 70,000 Series J Convertible Preferred Stock 115,267 115,267 Series K Convertible Preferred Stock 229,334 229,334 Series AA Convertible Preferred Stock 7,939,000 7,518,622 26,498,155 17,938,753
Accounting for Stock-Based Compensation Expense	Accounting for Stock-Based Compensation Expense We maintain equity compensation plans under which incentive stock options and non-qualified stock options are granted to employees, independent members of our Board of Directors and outside consultants. We recognize stock-based compensation expense over the requisite service period using the Black-Scholes formula to estimate the fair value of the stock options on the date of grant. Determining Fair Value of Stock Option Grants Valuation and Amortization Method - The fair value of each option award is estimated on the date of grant using the Black-Scholes pricing model based on certain assumptions. The estimated fair value of employee stock options is amortized to expense using the straight-line method over the vesting period. Expected Term - The Company uses the simplified calculation of expected life, as the Company does not currently have sufficient historical exercise data on which to base an estimate of expected term. Using this method, the expected term is determined using the average of the vesting period and the contractual life of the stock options granted. Expected Volatility - Expected volatility is based on the Company’s historical stock volatility data over the expected term of the award. Risk-Free Interest Rate - The Company bases the risk-free interest rate used in the Black-Scholes valuation method on the implied yield currently available on U.S. Treasury zero-coupon issues with an equivalent remaining term. Forfeitures - The Company records stock-based compensation expense only for those awards that are expected to vest. The Company estimated a forfeiture rate of 5% for awards granted based on historical experience and future expectations of options vesting. The Company used this historical rate as our assumption in calculating future stock-based compensation expense. The Company recognized stock-based compensation expense of $65,341 and $362,182 for the three months ended June 30, 2020 and 2019, respectively. The Company recognized stock-based compensation expense of $307,110 and $607,574 for the six months ended June 30, 2020 and 2019, respectively. The following table summarizes the effect of this stock-based compensation expense within each of the line items of our costs and expenses within our Consolidated Statements of Operations: For the Three Months Ended For the Six Months Ended June 30, June 30, 2020 2019 2020 2019 Cost of sales $ 5,107 $ 12,082 $ 13,063 $ 20,398 Research and development 26,137 49,948 64,963 84,573 Selling and marketing 6,358 28,959 20,294 51,078 General and administrative 27,739 271,193 208,780 451,525 Total stock-based compensation expense $ 65,341 $ 362,182 $ 307,110 $ 607,574
Fair Value of Financial Instruments	Fair Value of Financial Instruments Due to their short maturities, the carrying amounts for cash and cash equivalents, accounts receivable, accounts payable, accrued expenses and debt approximate their fair value. Long-term liabilities include only deferred revenue with a carrying value that approximates fair value.
Fair Value Measurements	Fair Value Measurements The Company follows the guidance of FASB ASC Topic 820, “ Fair Value Measurements and Disclosures The Company generally defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). The Company uses a three-tier fair value hierarchy, which classifies the inputs used in measuring fair values. These tiers include: Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring the Company to develop its own assumptions. A slight change in an unobservable input like volatility could have a significant impact on fair value measurement. Financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company has determined that its financial assets are classified within Level 1 in the fair value hierarchy. The development of the unobservable inputs for Level 3 fair value measurements and fair value calculations are the responsibility of the Company’s management. The following tables set forth the Company’s financial assets and liabilities that were accounted for at fair value on a recurring basis as of June 30, 2020: Fair value measurements at June 30, 2020 Quoted Significant (Level 2) Significant (Level 3) Equity Securities 362,905 362,905 - - Total Financial Assets $ 362,905 $ 362,905 $ - $ - The following tables set forth the Company’s financial assets and liabilities that were accounted for at fair value on a recurring basis as of December 31, 2019: Fair value measurements at December 31, 2019 Quoted Significant Significant Equity Securities 16,643 16,643 - - Total Financial Assets $ 16,643 $ 16,643 $ - $ -

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	6 Months Ended
	Jun. 30, 2020
Accounting Policies [Abstract]
Schedule of Disaggregation of Revenue	In the following table, revenue is disaggregated by primary geographical market, major product line, and timing of revenue recognition. In thousands of US dollars ($) Three Months Ended Six Months Ended Primary geographical markets 2020 2019 2020 2019 North America $ 162 $ 368 $ 307 $ 592 Europe 3 54 4 94 Asia 103 97 211 343 $ 268 $ 519 $ 522 $ 1,029 Three Months Ended Six Months Ended Major products/services lines 2020 2019 2020 2019 Hardware $ 122 $ 212 $ 217 $ 352 Consumables 51 91 107 153 Contract research services 34 111 44 349 Sample preparation accessories 33 35 58 35 Technical support/extended service contracts 17 28 36 67 Shipping and handling 6 14 15 19 Other 5 28 45 54 $ 268 $ 519 $ 522 $ 1,029 Three Months Ended Six Months Ended Timing of revenue recognition 2020 2019 2020 2019 Products transferred at a point in time $ 217 $ 506 $ 442 $ 1,007 Services transferred over time 51 13 80 22 $ 268 $ 519 $ 522 $ 1,029
Schedule of Contract Balances	Contract balances In thousands of US dollars ($) June 30, 2020 December 31, 2019 Receivables, which are included in ‘Accounts Receivable’ $ 121 $ 229 Contract liabilities (deferred revenue) 72 41
Schedule of Future Related to Performance Obligations	The following table includes estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) at the end of the reporting period. In thousands of US dollars ($) 2020 2021 2022 Total Extended warranty service $ 37 35 - $ 72
Schedule of Customer Concentration Risk Percentage	The following table illustrates the level of concentration as a percentage of total revenues during the three months and six months ended June 30, 2020 and 2019. For the Three Months Ended June 30, 2020 2019 Top Five Customers 71 % 47 % Federal Agencies 2 % 9 % For the Six Months Ended June 30, 2019 2019 Top Five Customers 70 % 55 % Federal Agencies 4 % 14 % The following table illustrates the level of concentration as a percentage of net accounts receivable balance as of June 30, 2020 and December 31, 2019. The Top Five Customers category may include federal agency receivable balances if applicable. June 30, 2020 December, 31, 2019 Top Five Customers 82 % 83 % Federal Agencies 5 % 17 %
Schedule of Computation of Loss Per Share	The following table illustrates our computation of loss per share for the three months and six months ended June 30, 2020 and 2019: For the Three Months Ended For the Six Months Ended June 30, June 30, 2020 2019 2020 2019 Numerator: Net loss $ (4,568,782 ) $ (2,766,842 ) $ (8,522,667 ) $ (4,822,015 ) Deemed dividend on beneficial conversion feature - (889,532 ) - (1,949,731 ) Preferred stock dividends (396,970 ) (420,489 ) (721,556 ) (776,099 ) Net loss applicable to common shareholders $ (4,965,752 ) $ (4,076,863 ) $ (9,244,223 ) $ (7,547,845 ) Denominator for basic and diluted loss per share: Weighted average common stock shares outstanding 2,914,659 1,837,913 2,765,132 1,780,881 Loss per common share – basic and diluted $ (1.70 ) $ (2.22 ) $ (3.34 ) $ (4.24 )
Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share	As of June 30, 2020 2019 Stock options 1,392,370 347,070 Convertible debt 3,905,867 692,715 Common stock warrants 12,761,126 8,880,554 Convertible preferred stock: Series D Convertible Preferred Stock 25,000 25,000 Series G Convertible Preferred Stock 26,857 26,857 Series H Convertible Preferred Stock 33,334 33,334 Series H2 Convertible Preferred Stock 70,000 70,000 Series J Convertible Preferred Stock 115,267 115,267 Series K Convertible Preferred Stock 229,334 229,334 Series AA Convertible Preferred Stock 7,939,000 7,518,622 26,498,155 17,938,753
Schedule of Stock Based Compensation Expense	The following table summarizes the effect of this stock-based compensation expense within each of the line items of our costs and expenses within our Consolidated Statements of Operations: For the Three Months Ended For the Six Months Ended June 30, June 30, 2020 2019 2020 2019 Cost of sales $ 5,107 $ 12,082 $ 13,063 $ 20,398 Research and development 26,137 49,948 64,963 84,573 Selling and marketing 6,358 28,959 20,294 51,078 General and administrative 27,739 271,193 208,780 451,525 Total stock-based compensation expense $ 65,341 $ 362,182 $ 307,110 $ 607,574
Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis	The following tables set forth the Company’s financial assets and liabilities that were accounted for at fair value on a recurring basis as of June 30, 2020: Fair value measurements at June 30, 2020 Quoted Significant (Level 2) Significant (Level 3) Equity Securities 362,905 362,905 - - Total Financial Assets $ 362,905 $ 362,905 $ - $ - The following tables set forth the Company’s financial assets and liabilities that were accounted for at fair value on a recurring basis as of December 31, 2019: Fair value measurements at December 31, 2019 Quoted Significant Significant Equity Securities 16,643 16,643 - - Total Financial Assets $ 16,643 $ 16,643 $ - $ -

Commitments and Contingencies (

Commitments and Contingencies (Tables)	6 Months Ended
	Jun. 30, 2020
Commitments and Contingencies Disclosure [Abstract]
Schedule of Future Minimum Rental Payments Required Under Operating Leases	Following is a schedule by years of future minimum rental payments required under operating leases with initial or remaining non-cancelable lease terms as of June 30, 2020: 2020 $ 84,480 Thereafter - Total Minimum Payments Required $ 84,480

Convertible Debt and Other De_2

Convertible Debt and Other Debt (Tables)	6 Months Ended
	Jun. 30, 2020
Debt Disclosure [Abstract]
Schedule of Convertible Debt and Outstanding Balances	The specific terms of the convertible notes and outstanding balances as of June 30, 2020 are listed in the tables below. Lender Inception Date Term Loan Amount Outstanding balance with OID Original Issue Discount (OID) Interest Rate Conversion Price Deferred Finance Fees Discount for conversion feature and warrants/shares Vision #1 February 15, 2018 (2)(3)(4) 6 months $ 100,000 $ 115,000 $ - 5 % 2.50 $ 9,000 $ 17,738 Auctus May 17, 2018 (2) 12 months $ 380,000 $ 166,703 $ 15,200 8 % 2.50 $ 15,200 $ 332,407 Carlino June 8, 2018 (1)(4) 6 months $ 50,000 $ 50,000 $ 2,500 2 % 7.50 $ 2,500 $ 3,271 GS June 16, 2018 (2) 9 months $ 130,000 $ 79,000 $ - 5 % 2.50 $ - $ - GS June 16, 2018 (2) 6 months $ 110,000 $ 79,000 $ - 5 % 2.50 $ - $ - Vision #4 June 26, 2018 (1)(2)(3)(4) 3 months $ 150,000 $ 86,250 $ - 5 % 2.50 $ - $ 30,862 Vision #5 July 17, 2018 (1) (2)(3)(4) 3 months $ 100,000 $ 105,000 $ 15,000 5 % 2.50 $ - $ 52,897 BHP July 19, 2018 (2) 12 months $ 184,685 $ 150,000 $ 34,685 10 % 2.50 $ - $ - Casale October 19, 2018 (1) 6 months $ 100,000 $ 100,000 $ - 5 % 7.50 $ - $ - Vision #6 November 13, 2018 (1) (2)(3)(4) 6 months $ 200,000 $ 220,000 $ - 5 % 2.50 $ - $ 168,634 James Gathard January 3, 2019 (1)(4) 6 months $ 50,000 $ 50,000 $ 2,500 24 % 7.50 $ 2,500 $ - Eagle Equities LLC February 21, 2019 (2) 12 months $ 215,000 $ 215,000 $ - 4 % 2.50 $ 15,000 $ 107,709 Crossover February 22, 2019 (2) 9 months $ 115,563 $ 115,562 $ 8,063 7 % 2.50 $ 2,500 $ - Casale March 18, 2019 (1) 6 months $ 100,000 $ 100,000 $ - 4 % 7.50 $ - $ 10,762 Auctus June 4, 2019 (2) 9 months $ 500,000 $ 302,484 $ - 8 % 2.50 $ 40,500 $ 70,631 LG Capital April 30, 2019 (2) 12 months $ 105,000 $ 80,000 $ - 4 % 2.50 $ 5,000 $ 3,286 LG Capital June 19, 2019 (2) 12 months $ 105,000 $ 105,000 $ - 4 % 2.50 $ 5,000 $ 2,646 Morningview Financial April 9, 2019 (2) 12 months $ 118,800 $ 88,800 $ 8,800 4 % 2.50 $ 3,000 $ - Vision #9 May 20, 2019 (1) (2)(4) 3 months $ 100,000 $ 100,000 $ - 5 % 2.50 $ - $ 13,439 Vision #10 June 7, 2019 (1) (2)(4) 6 months $ 125,000 $ 125,000 $ - 5 % 7.50 $ - $ 18,254 Eagle Equities LLC July 1, 2019 (2) 12 months $ 107,500 $ 107,500 $ - 4 % 2.50 $ 7,500 $ 85,791 C and B Holdings NY July 29, 2019 (2) 6 months $ 250,000 $ 250,000 $ - 4 % 2.50 $ - $ 36,835 LG Capital July 19, 2019 (2) 12 months $ 115,000 $ 115,000 $ - 4 % 2.50 $ 5,750 $ 15,460 Odyssey Capital July 19, 2019 (2) 12 months $ 130,000 $ 130,000 $ - 6 % 2.50 $ 6,500 $ - Morningview Financial August 6, 2019 (2) 12 months $ 108,000 $ 108,000 $ - 4 % 2.50 $ 11,000 $ - Sheila Bloom-Rosenberg August 14, 2019 (1)(4) 6 months $ 50,000 $ 50,000 $ - 2 % 7.50 $ - $ - LG Capital September 27, 2019 (2) 12 months $ 78,750 $ 78,750 $ - 4 % 2.50 $ 3,750 $ 13,759 LG Capital October 24, 2019 (2) 12 months $ 78,750 $ 78,750 $ - 4 % 2.50 $ 3,750 $ - GW October 25, 2019 12 months $ 105,000 $ 105,000 $ - 8 % 2.50 $ 5,000 $ - Odyssey Capital November 1, 2019 (2) 12 months $ 270,000 $ 270,000 $ - 6 % 2.50 $ 13,500 $ - C&B Holdings October 8, 2019 6 months $ 100,000 $ 100,000 $ - 4 % 7.50 $ - $ 5,725 Clay 11/15/2019 Loan 1 November 15, 2019 12 months $ 385,000 $ 385,000 $ 35,000 10 % 2.50 $ 35,000 $ 90,917 Clay 12/4/2019 Loan 2 December 4, 2019 12 months $ 495,000 $ 495,000 $ 45,000 10 % 2.50 $ 45,000 $ 56,387 Clay 12/20/2019 Loan 4 December 20, 2019 12 months $ 275,000 $ 275,000 $ 25,000 10 % 2.50 $ 25,000 $ 40,601 Clay 1/2/2020 Loan January 2, 2020 12 months $ 330,000 $ 330,000 $ 30,000 10 % 2.50 $ 30,000 $ 91,606 Clay 1/24/2020 Loan January 24, 2020 12 months $ 247,500 $ 247,500 $ 22,500 10 % 2.50 $ 22,500 $ 89,707 Clay 1/29/2020 Loan January 29, 2020 12 months $ 363,000 $ 363,000 $ 33,000 10 % 2.50 $ 33,000 $ 297,000 Clay 2/12/20 Loan February 12, 2020 12 months $ 275,000 $ 275,000 $ 25,000 10 % 2.50 $ 25,000 $ 225,000 Clay 2/21/20 Loan February 19, 2020 12 months $ 165,000 $ 165,000 $ 15,000 10 % 2.50 $ 15,000 $ 135,000 Clay 3/11/20 March 11, 2020 12 months $ 330,000 $ 330,000 $ 30,000 10 % 2.50 $ 30,000 $ 232,810 Clay 3/13/20 March 13, 2020 12 months $ 165,000 $ 165,000 $ 15,000 10 % 2.50 $ 15,000 $ 60,705 Clay 3/26/20 Loan March 26, 2020 12 months $ 111,100 $ 111,100 $ 10,100 10 % 2.50 $ 10,100 $ 90,900 Clay 4/8/20 Loan April 8, 2020 12 months $ 276,100 $ 276,100 $ 25,100 10 % 2.50 $ 25,000 $ 221,654 Clay 4/17/20 Loan April 17, 2020 12 months $ 143,750 $ 143,750 $ 18,750 10 % 2.50 $ - $ 96,208 Clay 4/22/20 Loan April 30, 2020 12 months $ 546,250 $ 546,250 $ 71,250 10 % 2.50 $ 47,500 $ 427,500 Clay 5/4/20 Loan May 7, 2020 12 months $ 460,000 $ 460,000 $ 60,000 10 % 2.50 $ 40,000 $ 360,000 Clay 5/11/20 Loan May 18, 2020 12 months $ 546,250 $ 546,250 $ 71,250 10 % 2.50 $ 35,500 $ 439,500 Clay 5/20/20 Loan June 2, 2020 12 months $ 902,750 $ 902,750 $ 117,750 10 % 2.50 $ 58,900 $ 708,500 Geer 6/1/20 Loan May 29, 2020 12 months $ 110,000 $ 110,000 $ 10,000 10 % 2.50 $ - $ - Clay 6/12/20 Loan June 12, 2020 12 months $ 57,500 $ 57,500 $ 7,500 10 % 2.50 $ 5,000 $ 45,000 Clay 6/22/20 Loan June 22, 2020 12 months $ 138,000 $ 138,000 $ 18,000 10 % 2.50 $ 12,000 $ 108,000 $ 10,147,999 $ 771,948 $ 666,450 $ 4,807,101 (1) The Note is past due. The Company and the lender are negotiating in good faith to extend the loan. (2) As of June 30, 2020 lender entered into a Standstill and Forbearance agreement (as described below). Loan is convertible at $2.50 until the expiration of the agreement. (3) Interest was capitalized and added to outstanding principal. (4) During the six months ended June 30, 2020 the Company entered into Rate Modification Agreements with these lenders. In these agreements five lenders agreed to reduce their interest rate and were granted the right to convert loans using a variable conversion price if other variable rate lenders converted at a variable rate.
Summary of Changes in Convertible Debt, Net of Unamortized Discounts	The following table provides a summary of the changes in convertible debt, net of unamortized discounts, during 2020: 2020 Balance at January 1, $ 6,121,338 Issuance of convertible debt, face value 5,435,950 Deferred financing cost (1,013,350 ) Beneficial conversion feature on convertible note (982,097 ) Debt discount from warrants issued with debt (2,705,996 ) Payments (1,257,250 ) Conversion of debt into equity (771,266 ) Accretion of interest and amortization of debt discount to interest expense 1,397,121 Balance at June 30, 6,224,450 Less: current portion 6,224,450 Convertible debt, long-term portion $ –
Schedule of Merchant Agreements	The following table shows our Merchant Agreements as of June 30, 2020: Inception Date Purchase Price Purchased Amount Outstanding Balance Daily Payment Rate Deferred August 5, 2019 $ 600,000 $ 816,000 $ 174,943 $ 4,533 $ 6,000 August 19, 2019 350,000 479,500 245,355 2,664 3,000 August 23, 2019 175,000 239,750 87,192 1,410 1,750 September 19, 2019 275,000 384,275 183,348 2,138 5,000 $ 1,400,000 $ 1,919,525 $ 690,838 $ 10,745 $ 15,750 The following table shows our Merchant Agreements as of December 31, 2019: Inception Date Purchase Price Purchased Amount Outstanding Balance Daily Payment Rate Deferred Finance Fees August 5, 2019 $ 600,000 $ 816,000 $ 421,024 4,533 $ 6,000 August 19, 2019 350,000 479,500 272,315 2,664 3,000 August 23, 2019 175,000 239,750 132,284 1,410 1,750 September 19, 2019 275,000 384,275 256,812 2,138 5,000 $ 1,400,000 $ 1,919,525 $ 1,082,435 $ 10,745 $ 15,750

Stockholders' Deficit (Tables)

Stockholders' Deficit (Tables)	6 Months Ended
	Jun. 30, 2020
Equity [Abstract]
Schedule of Concerning Options and Warrants Outstanding and Exercisable	The following table summarizes information concerning options and warrants outstanding and exercisable: Stock Options Warrants Weighted Weighted Average Average Shares price per share Shares price per share Shares Total Balance outstanding, December 31, 2019 1,396,302 $ 0.71 9,893,034 $ 3.52 11,289,336 10,148,543 Granted - - 2,907,870 3.50 2,907,870 Exercised - - - - - Expired - - (39,778 ) $ 8.40 (39,778 ) Forfeited (3,932 ) 0.69 - - (3,932 ) Balance outstanding, June 30, 2020 1,392,370 $ 0.69 12,761,126 $ 3.50 14,153,496 13,203,517

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Unrealized gain	$ 196,891		$ 346,262
Forfeiture rate			5.00%
Stock-based compensation expense	65,341	$ 362,182	$ 307,110	$ 607,574
Everest Investments Holdings S.A. [Member]
Sale of stock number of shares received			100,250
Fair value of investment	$ 362,905		$ 362,905
Unrealized gain			$ 346,262

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Schedule of Disaggregation of Revenue (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Revenue	$ 268,154	$ 518,663	$ 522,027	$ 1,028,903
Hardware [Member]
Revenue	122,000	212,000	217,000	352,000
Consumables [Member]
Revenue	51,000	91,000	107,000	153,000
Contract Research Services [Member]
Revenue	34,000	111,000	44,000	349,000
Sample Preparation Accessories [Member]
Revenue	33,000	35,000	58,000	35,000
Technical Support/Extended Service Contracts [Member]
Revenue	17,000	28,000	36,000	67,000
Shipping and Handling [Member]
Revenue	6,000	14,000	15,000	19,000
Other [Member]
Revenue	5,000	28,000	45,000	54,000
Products Transferred at a Point in Time [Member]
Revenue	217,000	506,000	442,000	1,007,000
Services Transferred Over Time [Member]
Revenue	51,000	13,000	80,000	22,000
North America [Member]
Revenue	162,000	368,000	307,000	592,000
Europe [Member]
Revenue	3,000	54,000	4,000	94,000
Asia [Member]
Revenue	$ 103,000	$ 97,000	$ 211,000	$ 343,000

Summary of Significant Accoun_6

Summary of Significant Accounting Policies - Schedule of Contract Balances (Details) - USD ($)	Jun. 30, 2020	Dec. 31, 2019
Accounting Policies [Abstract]
Receivables, which are included in 'Accounts Receivable'	$ 121,000	$ 229,000
Contract liabilities (deferred revenue)	$ 72,000	$ 41,000

Summary of Significant Accoun_7

Summary of Significant Accounting Policies - Schedule of Future Related to Performance Obligations (Details)	Jun. 30, 2020USD ($)
Extended warranty service	$ 72,000
2020 [Member]
Extended warranty service	37,000
2021 [Member]
Extended warranty service	35,000
2022 [Member]
Extended warranty service

Summary of Significant Accoun_8

Summary of Significant Accounting Policies - Schedule of Customer Concentration Risk Percentage (Details)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019
Top Five Customers [Member] | Revenue [Member]
Concentration credit risk percentage	71.00%	47.00%	70.00%	55.00%
Top Five Customers [Member] | Accounts Receivable [Member]
Concentration credit risk percentage			82.00%		83.00%
Federal Agencies [Member] | Revenue [Member]
Concentration credit risk percentage	2.00%	9.00%	4.00%	14.00%
Federal Agencies [Member] | Accounts Receivable [Member]
Concentration credit risk percentage			5.00%		17.00%

Summary of Significant Accoun_9

Summary of Significant Accounting Policies - Schedule of Computation of Loss Per Share (Details) - USD ($)	3 Months Ended				6 Months Ended
	Jun. 30, 2020	Mar. 31, 2020	Jun. 30, 2019	Mar. 31, 2019	Jun. 30, 2020	Jun. 30, 2019
Accounting Policies [Abstract]
Net loss	$ (4,568,782)	$ (3,953,855)	$ (2,766,842)	$ (2,055,173)	$ (8,522,667)	$ (4,822,015)
Deemed dividend on beneficial conversion feature			(889,532)			(1,949,731)
Preferred stock dividends	(396,970)		(420,489)		(721,556)	(776,099)
Net loss applicable to common shareholders	$ (4,965,752)		$ (4,076,863)		$ (9,244,223)	$ (7,547,845)
Weighted average common stock shares outstanding	2,914,659		1,837,913		2,765,132	1,780,881
Loss per common share - basic and diluted	$ (1.70)		$ (2.22)		$ (3.34)	$ (4.24)

Summary of Significant Accou_10

Summary of Significant Accounting Policies - Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Total potentially dilutive shares	26,498,155	17,938,753
Stock Options [Member]
Total potentially dilutive shares	1,392,370	347,070
Convertible Debt [Member]
Total potentially dilutive shares	3,905,867	692,715
Common Stock Warrants [Member]
Total potentially dilutive shares	12,761,126	8,880,554
Series D Convertible Preferred Stock [Member]
Total potentially dilutive shares	25,000	25,000
Series G Convertible Preferred Stock [Member]
Total potentially dilutive shares	26,857	26,857
Series H Convertible Preferred Stock [Member]
Total potentially dilutive shares	33,334	33,334
Series H2 Convertible Preferred Stock [Member]
Total potentially dilutive shares	70,000	70,000
Series J Convertible Preferred Stock [Member]
Total potentially dilutive shares	115,267	115,267
Series K Convertible Preferred Stock [Member]
Total potentially dilutive shares	7,939,000	229,334
Series AA Convertible Preferred Stock [Member]
Total potentially dilutive shares	7,939,000	7,518,622

Summary of Significant Accou_11

Summary of Significant Accounting Policies - Schedule of Stock Based Compensation Expense (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Total stock-based compensation expense	$ 65,341	$ 362,182	$ 307,110	$ 607,574
Cost of Sales [Member]
Total stock-based compensation expense	5,107	12,082	13,063	20,398
Research and Development [Member]
Total stock-based compensation expense	26,137	49,948	64,963	84,573
Selling and Marketing [Member]
Total stock-based compensation expense	6,358	28,959	20,294	51,078
General and Administrative [Member]
Total stock-based compensation expense	$ 27,739	$ 271,193	$ 208,780	$ 451,525

Summary of Significant Accou_12

Summary of Significant Accounting Policies - Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - USD ($)	Jun. 30, 2020	Dec. 31, 2019
Total Financial Assets	$ 362,905	$ 16,643
Quoted Prices in Active Markets (Level 1) [Member]
Total Financial Assets	362,905	16,643
Significant Other Observable Inputs (Level 2) [Member]
Total Financial Assets
Significant Unobservable Inputs (Level 3) [Member]
Total Financial Assets
Equity Securities [Member]
Total Financial Assets	362,905	16,643
Equity Securities [Member] | Quoted Prices in Active Markets (Level 1) [Member]
Total Financial Assets	362,905	16,643
Equity Securities [Member] | Significant Other Observable Inputs (Level 2) [Member]
Total Financial Assets
Equity Securities [Member] | Significant Unobservable Inputs (Level 3) [Member]
Total Financial Assets

Commitments and Contingencies_2

Commitments and Contingencies (Details Narrative) - USD ($)	6 Months Ended
	Jun. 30, 2020	Dec. 31, 2019
Operating liability	$ 136,385
Right of use asset leases	40,659	$ 76,586
Operating lease liability	40,659	$ 76,586
Medford [Member]
Lease monthly payments	$ 7,130
Lease expire date	Dec. 30, 2020
Lease expiration term	The lease shall be automatically extended for an additional three years unless either party terminates at least six months prior to the expiration of the current lease term.
Corporate Office [Member]
Lease monthly payments	$ 6,950
Lease expire date	Dec. 31, 2020

Commitments and Contingencies -

Commitments and Contingencies - Schedule of Future Minimum Rental Payments Required Under Operating Leases (Details)	Jun. 30, 2020USD ($)
Commitments and Contingencies Disclosure [Abstract]
2020	$ 84,480
Thereafter
Total Minimum Payments Required	$ 84,480

Loan Receivable (Details Narrat

Loan Receivable (Details Narrative) - USD ($)	6 Months Ended
	Jun. 30, 2020	Dec. 31, 2019
Loans receivable	$ 531,250
Cannaworx [Member]
Loans receivable	43,750
Two Loans [Member] | Cannaworx [Member]
Payment of loans	$ 575,000
Debt term	1 year
Loan One [Member] | Cannaworx [Member]
Payment of loans	$ 325,000
Interest rate	12.00%
Loan Two [Member] | Cannaworx [Member]
Payment of loans	$ 250,000
Interest rate	18.00%

Convertible Debt and Other De_3

Convertible Debt and Other Debt (Details Narrative) - USD ($)	Feb. 28, 2020	Oct. 11, 2019	Oct. 02, 2019	Sep. 09, 2019	Jun. 30, 2018	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019	Dec. 13, 2019	Nov. 15, 2019
Proceeds from convertible notes								$ 4,422,600	$ 3,339,050
Unamortized debt discount						$ 3,923,549		3,923,549		$ 619,227
Repayment of notes								1,257,250	2,533,985
Interest expense						1,724,879	$ 1,074,488	3,296,679	$ 1,587,194
United States [Member]
Loan amount						$ 527,039		$ 527,039
Lenders [Member]
Issuance of warrants to purchase of common stock shares						495,000		495,000
Fair value of warrants								$ 969,745
Merchant Lenders [Member]
Issuance of warrants to purchase of common stock												969,745
Issuance of warrants to purchase of common stock shares												495,000
Warrants expiration period												3 years
Warrant exercise price per share												$ 3.50
Interest expense								152,552
Chief Executive Officer [Member]
Loans outstanding						$ 690,838		$ 690,838
Standstill and Forbearance Agreements [Member]
Fees amount						$ 1,660,000
Standstill and Forbearance Agreements [Member] | Lenders [Member]
Convertible promissory notes											$ 2,267,066
Merchant Agreements [Member] | Minimum [Member]
Interest rate						6.00%		6.00%
Merchant Agreements [Member] | Maximum [Member]
Interest rate						76.00%		76.00%
Payroll Protection Program [Member]
Debt term								2 years
Interest rate						1.00%		1.00%
Loan amount						$ 377,039		$ 377,039
Eonomic Injury Disaster Loan Program [Member]
Interest rate
Loan amount
Monthly payments								$ 731
Principal balance due description								Interest beginning in June 2021. The balance of the principal will be due in 30 years.
Convertible Notes [Member]
Proceeds from convertible notes								$ 4,400,000
Debt term								12 months
Interest rate						10.00%		10.00%
Debt conversion price per share						$ 2.50		$ 2.50
Unamortized debt discount						$ 2,705,996		$ 2,705,996
Beneficial conversion feature								982,097
Amortization of debt discount								1,397,121
Convertible Debentures and Other Convertible Notes [Member]
Unamortized debt discount						$ 3,923,549		$ 3,923,549
New Loan [Member]
Non-cash expenses for warrants issued								977,622
Debt instrument description								We refinanced certain convertible loans during the quarter ended June 30, 2020 at substantially the same terms for extensions ranging over a period of three to six months. We amortized any remaining unamortized debt discount as of the modification date over the remaining, extended term of the new loans. We applied ASC 470 of modification accounting to the debt instruments which were modified during the quarter or those settled with new notes issued concurrently for the same amounts but different maturity dates. The terms such as the interest rate, prepayment penalties, and default rates will be the same over the new extensions. According to ASC 470, an exchange of debt instruments between or a modification of a debt instrument by a debtor and a creditor in a nontroubled debt situation is deemed to have been accomplished with debt instruments that are substantially different if the present value of the cash flows under the terms of the new debt instrument is at least 10 percent different from the present value of the remaining cash flows under the terms of the original instrument. If the terms of a debt instrument are changed or modified and the cash flow effect on a present value basis is less than 10 percent, the debt instruments are not considered to be substantially different and will be accounted for as modifications.
New Loan [Member] | Minimum [Member]
Interest rate						10.00%		10.00%
Original Debt on Five Loans [Member]
Interest rate						10.00%		10.00%
Gain on extinguishment of debt								$ 2,800,000
Non-Convertible Loans [Member]
Issuance of warrants to purchase of common stock						463,500		463,500
Issuance of warrants to purchase of common stock shares						150,000		150,000
Warrants expiration period						5 years		5 years
Warrant exercise price per share						$ 3.50		$ 3.50
Repayment of notes								$ 275,000
Fair value of warrants								185,660
Non-Convertible Loans [Member] | Private Investor [Member]
Debt term		1 month
Interest rate		2.00%
Proceeds from loan	$ 966,500	$ 25,000		$ 966,500
Loan amount						$ 691,500		691,500
Non-Convertible Loans [Member] | Holder [Member]
Interest rate			10.00%
Proceeds from loan			$ 170,000
Number of shares issued			1,200
Other Notes [Member]
Amortization of debt discount								353,790
Non-Convertible Loan [Member] | Private Investor [Member]
Debt term					1 year
Interest rate					15.00%
Loan amount					$ 15,000
Non-Convertible Loan [Member] | Related Parties [Member]
Loan amount						$ 75,000		$ 75,000
Non-Convertible Loan [Member] | Related Parties [Member] | Minimum [Member]
Interest rate						0.00%		0.00%
Non-Convertible Loan [Member] | Related Parties [Member] | Maximum [Member]
Interest rate						15.00%		15.00%

Convertible Debt and Other De_4

Convertible Debt and Other Debt - Schedule of Convertible Debt and Outstanding Balances (Details) - USD ($)		6 Months Ended
		Jun. 30, 2020	Dec. 31, 2019
Loan Amount		$ 5,435,950
Deferred Finance Fees		15,750	$ 15,750
Convertible Notes [Member]
Outstanding balance with OID		10,147,999
Original Issue Discount (OID)		771,948
Deferred Finance Fees		666,450
Discount for conversion feature and warrants/shares		$ 4,807,101
Convertible Notes [Member] | Convertible Debt One [Member]
Lender		Vision #1
Inception Date	[1],[2],[3]	Feb. 15, 2018
Term		6 months
Loan Amount		$ 100,000
Outstanding balance with OID		115,000
Original Issue Discount (OID)
Interest Rate		5.00%
Conversion Price		$ 2.50
Deferred Finance Fees		$ 9,000
Discount for conversion feature and warrants/shares		$ 17,738
Convertible Notes [Member] | Convertible Debt Two [Member]
Lender		Auctus
Inception Date	[1]	May 17, 2018
Term		12 months
Loan Amount		$ 380,000
Outstanding balance with OID		166,703
Original Issue Discount (OID)		$ 15,200
Interest Rate		8.00%
Conversion Price		$ 2.50
Deferred Finance Fees		$ 15,200
Discount for conversion feature and warrants/shares		$ 332,407
Convertible Notes [Member] | Convertible Debt Three [Member]
Lender		Carlino
Inception Date	[2],[4]	Jun. 8, 2018
Term		6 months
Loan Amount		$ 50,000
Outstanding balance with OID		50,000
Original Issue Discount (OID)		$ 2,500
Interest Rate		2.00%
Conversion Price		$ 7.50
Deferred Finance Fees		$ 2,500
Discount for conversion feature and warrants/shares		$ 3,271
Convertible Notes [Member] | Convertible Debt Four [Member]
Lender		GS
Inception Date	[1]	Jun. 16, 2018
Term		9 months
Loan Amount		$ 130,000
Outstanding balance with OID		79,000
Original Issue Discount (OID)
Interest Rate		5.00%
Conversion Price		$ 2.50
Deferred Finance Fees
Discount for conversion feature and warrants/shares
Convertible Notes [Member] | Convertible Debt Five [Member]
Lender		GS
Inception Date	[1]	Jun. 16, 2018
Term		6 months
Loan Amount		$ 110,000
Outstanding balance with OID		79,000
Original Issue Discount (OID)
Interest Rate		5.00%
Conversion Price		$ 2.50
Deferred Finance Fees
Discount for conversion feature and warrants/shares
Convertible Notes [Member] | Convertible Debt Six [Member]
Lender		Vision #4
Inception Date	[1],[2],[3],[4]	Jun. 26, 2018
Term		3 months
Loan Amount		$ 150,000
Outstanding balance with OID		86,250
Original Issue Discount (OID)
Interest Rate		5.00%
Conversion Price		$ 2.50
Deferred Finance Fees
Discount for conversion feature and warrants/shares		$ 30,862
Convertible Notes [Member] | Convertible Debt Seven [Member]
Lender		Vision #5
Inception Date	[1],[4]	Jul. 17, 2018
Term		3 months
Loan Amount		$ 100,000
Outstanding balance with OID		105,000
Original Issue Discount (OID)		$ 15,000
Interest Rate		5.00%
Conversion Price		$ 2.50
Deferred Finance Fees
Discount for conversion feature and warrants/shares		$ 52,897
Convertible Notes [Member] | Convertible Debt Eight [Member]
Lender		BHP
Inception Date	[1],[2],[3]	Jul. 19, 2018
Term		12 months
Loan Amount		$ 184,685
Outstanding balance with OID		150,000
Original Issue Discount (OID)		$ 34,685
Interest Rate		10.00%
Conversion Price		$ 2.50
Deferred Finance Fees
Discount for conversion feature and warrants/shares
Convertible Notes [Member] | Convertible Debt Nine [Member]
Lender		Casale
Inception Date	[4]	Oct. 19, 2018
Term		6 months
Loan Amount		$ 100,000
Outstanding balance with OID		100,000
Original Issue Discount (OID)
Interest Rate		5.00%
Conversion Price		$ 7.50
Deferred Finance Fees
Discount for conversion feature and warrants/shares
Convertible Notes [Member] | Convertible Debt Ten [Member]
Lender		Vision #6
Inception Date	[1],[2],[3],[4]	Nov. 13, 2018
Term		6 months
Loan Amount		$ 200,000
Outstanding balance with OID		220,000
Original Issue Discount (OID)
Interest Rate		5.00%
Conversion Price		$ 2.50
Deferred Finance Fees
Discount for conversion feature and warrants/shares		$ 168,634
Convertible Notes [Member] | Convertible Debt Eleven [Member]
Lender		James Gathard
Inception Date	[2],[4]	Jan. 3, 2019
Term		6 months
Loan Amount		$ 50,000
Outstanding balance with OID		50,000
Original Issue Discount (OID)		$ 2,500
Interest Rate		24.00%
Conversion Price		$ 7.50
Deferred Finance Fees		$ 2,500
Discount for conversion feature and warrants/shares
Convertible Notes [Member] | Convertible Debt Twelve [Member]
Lender		Eagle Equities LLC
Inception Date	[1]	Feb. 21, 2019
Term		12 months
Loan Amount		$ 215,000
Outstanding balance with OID		215,000
Original Issue Discount (OID)
Interest Rate		4.00%
Conversion Price		$ 2.50
Deferred Finance Fees		$ 15,000
Discount for conversion feature and warrants/shares		$ 107,709
Convertible Notes [Member] | Convertible Debt Thirteen [Member]
Lender		Crossover
Inception Date	[1]	Feb. 22, 2019
Term		9 months
Loan Amount		$ 115,563
Outstanding balance with OID		115,562
Original Issue Discount (OID)		$ 8,063
Interest Rate		7.00%
Conversion Price		$ 2.50
Deferred Finance Fees		$ 2,500
Discount for conversion feature and warrants/shares
Convertible Notes [Member] | Convertible Debt Fourteen [Member]
Lender		Casale
Inception Date	[4]	Mar. 18, 2019
Term		6 months
Loan Amount		$ 100,000
Outstanding balance with OID		100,000
Original Issue Discount (OID)
Interest Rate		4.00%
Conversion Price		$ 7.50
Deferred Finance Fees
Discount for conversion feature and warrants/shares		$ 10,762
Convertible Notes [Member] | Convertible Debt Fifteen [Member]
Lender		Auctus
Inception Date	[1]	Jun. 4, 2019
Term		9 months
Loan Amount		$ 500,000
Outstanding balance with OID		302,484
Original Issue Discount (OID)
Interest Rate		8.00%
Conversion Price		$ 2.50
Deferred Finance Fees		$ 40,500
Discount for conversion feature and warrants/shares
Convertible Notes [Member] | Convertible Debt Sixteen [Member]
Lender		LG Capital
Inception Date	[1]	Apr. 30, 2019
Term		12 months
Loan Amount		$ 105,000
Outstanding balance with OID		80,000
Original Issue Discount (OID)
Interest Rate		4.00%
Conversion Price		$ 2.50
Deferred Finance Fees		$ 5,000
Discount for conversion feature and warrants/shares		$ 3,286
Convertible Notes [Member] | Convertible Debt Seventeen [Member]
Lender		LG Capital
Inception Date	[1]	Jun. 19, 2019
Term		12 months
Loan Amount		$ 105,000
Outstanding balance with OID		105,000
Original Issue Discount (OID)
Interest Rate		4.00%
Conversion Price		$ 2.50
Deferred Finance Fees		$ 5,000
Discount for conversion feature and warrants/shares		$ 2,646
Convertible Notes [Member] | Convertible Debt Eighteen [Member]
Lender		Morningview Financial
Inception Date	[1]	Apr. 9, 2019
Term		12 months
Loan Amount		$ 118,800
Outstanding balance with OID		88,800
Original Issue Discount (OID)		$ 8,800
Interest Rate		4.00%
Conversion Price		$ 2.50
Deferred Finance Fees		$ 3,000
Discount for conversion feature and warrants/shares
Convertible Notes [Member] | Convertible Debt Nineteen [Member]
Lender		Vision #9
Inception Date	[1],[2],[4]	May 20, 2019
Term		3 months
Loan Amount		$ 100,000
Outstanding balance with OID		100,000
Original Issue Discount (OID)
Interest Rate		5.00%
Conversion Price		$ 2.50
Deferred Finance Fees
Discount for conversion feature and warrants/shares		$ 13,439
Convertible Notes [Member] | Convertible Debt Twenty [Member]
Lender		Vision #10
Inception Date	[1],[2],[4]	Jun. 7, 2019
Term		6 months
Loan Amount		$ 125,000
Outstanding balance with OID		125,000
Original Issue Discount (OID)
Interest Rate		5.00%
Conversion Price		$ 7.50
Deferred Finance Fees
Discount for conversion feature and warrants/shares		$ 18,254
Convertible Notes [Member] | Convertible Debt Twenty One [Member]
Lender		Eagle Equities LLC
Inception Date	[1]	Jul. 1, 2019
Term		12 months
Loan Amount		$ 107,500
Outstanding balance with OID		107,500
Original Issue Discount (OID)
Interest Rate		4.00%
Conversion Price		$ 2.50
Deferred Finance Fees		$ 7,500
Discount for conversion feature and warrants/shares		$ 85,791
Convertible Notes [Member] | Convertible Debt Twenty Two [Member]
Lender		C and B Holdings NY
Inception Date	[1]	Jul. 29, 2019
Term		6 months
Loan Amount		$ 250,000
Outstanding balance with OID		250,000
Original Issue Discount (OID)
Interest Rate		4.00%
Conversion Price		$ 2.50
Deferred Finance Fees
Discount for conversion feature and warrants/shares		$ 36,835
Convertible Notes [Member] | Convertible Debt Twenty Three [Member]
Lender		LG Capital
Inception Date	[1]	Jul. 19, 2019
Term		12 months
Loan Amount		$ 115,000
Outstanding balance with OID		115,000
Original Issue Discount (OID)
Interest Rate		4.00%
Conversion Price		$ 2.50
Deferred Finance Fees		$ 5,750
Discount for conversion feature and warrants/shares		$ 15,460
Convertible Notes [Member] | Convertible Debt Twenty Four [Member]
Lender		Odyssey Capital
Inception Date	[1]	Jul. 19, 2019
Term		12 months
Loan Amount		$ 130,000
Outstanding balance with OID		130,000
Original Issue Discount (OID)
Interest Rate		6.00%
Conversion Price		$ 2.50
Deferred Finance Fees		$ 6,500
Discount for conversion feature and warrants/shares
Convertible Notes [Member] | Convertible Debt Twenty Five [Member]
Lender		Morningview Financial
Inception Date	[1]	Aug. 6, 2019
Term		12 months
Loan Amount		$ 108,000
Outstanding balance with OID		108,000
Original Issue Discount (OID)
Interest Rate		4.00%
Conversion Price		$ 2.50
Deferred Finance Fees		$ 11,000
Discount for conversion feature and warrants/shares
Convertible Notes [Member] | Convertible Debt Twenty Six [Member]
Lender		Sheila Bloom-Rosenberg
Inception Date	[2],[4]	Aug. 14, 2019
Term		6 months
Loan Amount		$ 50,000
Outstanding balance with OID		50,000
Original Issue Discount (OID)
Interest Rate		2.00%
Conversion Price		$ 7.50
Deferred Finance Fees
Discount for conversion feature and warrants/shares
Convertible Notes [Member] | Convertible Debt Twenty Seven [Member]
Lender		LG Capital
Inception Date	[1]	Sep. 27, 2019
Term		12 months
Loan Amount		$ 78,750
Outstanding balance with OID		78,750
Original Issue Discount (OID)
Interest Rate		4.00%
Conversion Price		$ 2.50
Deferred Finance Fees		$ 3,750
Discount for conversion feature and warrants/shares		$ 13,759
Convertible Notes [Member] | Convertible Debt Twenty Eight [Member]
Lender		LG Capital
Inception Date	[1]	Oct. 24, 2019
Term		12 months
Loan Amount		$ 78,750
Outstanding balance with OID		78,750
Original Issue Discount (OID)
Interest Rate		4.00%
Conversion Price		$ 2.50
Deferred Finance Fees		$ 3,750
Discount for conversion feature and warrants/shares
Convertible Notes [Member] | Convertible Debt Twenty Nine [Member]
Lender		GW
Inception Date		Oct. 25, 2019
Term		12 months
Loan Amount		$ 105,000
Outstanding balance with OID		105,000
Original Issue Discount (OID)
Interest Rate		8.00%
Conversion Price		$ 2.50
Deferred Finance Fees		$ 5,000
Discount for conversion feature and warrants/shares
Convertible Notes [Member] | Convertible Debt Thirty [Member]
Lender		Odyssey Capital
Inception Date	[1]	Nov. 1, 2019
Term		12 months
Loan Amount		$ 270,000
Outstanding balance with OID		270,000
Original Issue Discount (OID)
Interest Rate		6.00%
Conversion Price		$ 2.50
Deferred Finance Fees		$ 13,500
Discount for conversion feature and warrants/shares
Convertible Notes [Member] | Convertible Debt Thirty One [Member]
Lender		C&B Holdings
Inception Date		Oct. 8, 2019
Term		6 months
Loan Amount		$ 100,000
Outstanding balance with OID		100,000
Original Issue Discount (OID)
Interest Rate		4.00%
Conversion Price		$ 7.50
Deferred Finance Fees
Discount for conversion feature and warrants/shares		$ 5,725
Convertible Notes [Member] | Convertible Debt Thirty Two [Member]
Lender		Clay 11/15/2019 Loan 1
Inception Date		Nov. 15, 2019
Term		12 months
Loan Amount		$ 385,000
Outstanding balance with OID		385,000
Original Issue Discount (OID)		$ 35,000
Interest Rate		10.00%
Conversion Price		$ 2.50
Deferred Finance Fees		$ 35,000
Discount for conversion feature and warrants/shares		$ 90,917
Convertible Notes [Member] | Convertible Debt Thirty Three [Member]
Lender		Clay 12/4/2019 Loan 2
Inception Date		Dec. 4, 2019
Term		12 months
Loan Amount		$ 495,000
Outstanding balance with OID		495,000
Original Issue Discount (OID)		$ 45,000
Interest Rate		10.00%
Conversion Price		$ 2.50
Deferred Finance Fees		$ 45,000
Discount for conversion feature and warrants/shares		$ 56,387
Convertible Notes [Member] | Convertible Debt Thirty Four [Member]
Lender		Clay 12/20/2019 Loan 4
Inception Date		Dec. 20, 2019
Term		12 months
Loan Amount		$ 275,000
Outstanding balance with OID		275,000
Original Issue Discount (OID)		$ 25,000
Interest Rate		10.00%
Conversion Price		$ 2.50
Deferred Finance Fees		$ 25,000
Discount for conversion feature and warrants/shares		$ 40,601
Convertible Notes [Member] | Convertible Debt Thirty Five [Member]
Lender		Clay 1/2/2020 Loan
Inception Date		Jan. 2, 2020
Term		12 months
Loan Amount		$ 330,000
Outstanding balance with OID		330,000
Original Issue Discount (OID)		$ 30,000
Interest Rate		10.00%
Conversion Price		$ 2.50
Deferred Finance Fees		$ 30,000
Discount for conversion feature and warrants/shares		$ 91,606
Convertible Notes [Member] | Convertible Debt Thirty Six [Member]
Lender		Clay 1/24/2020 Loan
Inception Date		Jan. 24, 2020
Term		12 months
Loan Amount		$ 247,500
Outstanding balance with OID		247,500
Original Issue Discount (OID)		$ 22,500
Interest Rate		10.00%
Conversion Price		$ 2.50
Deferred Finance Fees		$ 22,500
Discount for conversion feature and warrants/shares		$ 89,707
Convertible Notes [Member] | Convertible Debt Thirty Seven [Member]
Lender		Clay 1/29/2020 Loan
Inception Date		Jan. 29, 2020
Term		12 months
Loan Amount		$ 363,000
Outstanding balance with OID		363,000
Original Issue Discount (OID)		$ 33,000
Interest Rate		10.00%
Conversion Price		$ 2.50
Deferred Finance Fees		$ 33,000
Discount for conversion feature and warrants/shares		$ 297,000
Convertible Notes [Member] | Convertible Debt Thirty Eight [Member]
Lender		Clay 2/12/20 Loan
Inception Date		Feb. 12, 2020
Term		12 months
Loan Amount		$ 275,000
Outstanding balance with OID		275,000
Original Issue Discount (OID)		$ 25,000
Interest Rate		10.00%
Conversion Price		$ 2.50
Deferred Finance Fees		$ 25,000
Discount for conversion feature and warrants/shares		$ 225,000
Convertible Notes [Member] | Convertible Debt Thirty Nine [Member]
Lender		Clay 2/21/20 Loan
Inception Date		Feb. 19, 2020
Term		12 months
Loan Amount		$ 165,000
Outstanding balance with OID		165,000
Original Issue Discount (OID)		$ 15,000
Interest Rate		10.00%
Conversion Price		$ 2.50
Deferred Finance Fees		$ 15,000
Discount for conversion feature and warrants/shares		$ 135,000
Convertible Notes [Member] | Convertible Debt Forty [Member]
Lender		Clay 3/11/20
Inception Date		Mar. 11, 2020
Term		12 months
Loan Amount		$ 330,000
Outstanding balance with OID		330,000
Original Issue Discount (OID)		$ 30,000
Interest Rate		10.00%
Conversion Price		$ 2.50
Deferred Finance Fees		$ 30,000
Discount for conversion feature and warrants/shares		$ 232,810
Convertible Notes [Member] | Convertible Debt Forty One [Member]
Lender		Clay 3/13/20
Inception Date		Mar. 13, 2020
Term		12 months
Loan Amount		$ 165,000
Outstanding balance with OID		165,000
Original Issue Discount (OID)		$ 15,000
Interest Rate		10.00%
Conversion Price		$ 2.50
Deferred Finance Fees		$ 15,000
Discount for conversion feature and warrants/shares		$ 60,705
Convertible Notes [Member] | Convertible Debt Forty Two [Member]
Lender		Clay 3/26/20 Loan
Inception Date		Mar. 26, 2020
Term		12 months
Loan Amount		$ 111,100
Outstanding balance with OID		111,100
Original Issue Discount (OID)		$ 10,100
Interest Rate		10.00%
Conversion Price		$ 2.50
Deferred Finance Fees		$ 10,100
Discount for conversion feature and warrants/shares		$ 90,900
Convertible Notes [Member] | Convertible Debt Forty Three [Member]
Lender		Clay 4/8/20 Loan
Inception Date		Apr. 8, 2020
Term		12 months
Loan Amount		$ 276,100
Outstanding balance with OID		276,100
Original Issue Discount (OID)		$ 25,100
Interest Rate		10.00%
Conversion Price		$ 2.50
Deferred Finance Fees		$ 25,000
Discount for conversion feature and warrants/shares		$ 221,654
Convertible Notes [Member] | Convertible Debt Forty four [Member]
Lender		Clay 4/17/20 Loan
Inception Date		Apr. 17, 2020
Term		12 months
Loan Amount		$ 143,750
Outstanding balance with OID		143,750
Original Issue Discount (OID)		$ 18,750
Interest Rate		10.00%
Conversion Price		$ 2.50
Deferred Finance Fees
Discount for conversion feature and warrants/shares		$ 96,208
Convertible Notes [Member] | Convertible Debt Forty Five [Member]
Lender		Clay 4/22/20 Loan
Inception Date		Apr. 30, 2020
Term		12 months
Loan Amount		$ 546,250
Outstanding balance with OID		546,250
Original Issue Discount (OID)		$ 71,250
Interest Rate		10.00%
Conversion Price		$ 2.50
Deferred Finance Fees		$ 47,500
Discount for conversion feature and warrants/shares		$ 427,500
Convertible Notes [Member] | Convertible Debt Forty Six [Member]
Lender		Clay 5/4/20 Loan
Inception Date		May 7, 2020
Term		12 months
Loan Amount		$ 460,000
Outstanding balance with OID		460,000
Original Issue Discount (OID)		$ 60,000
Interest Rate		10.00%
Conversion Price		$ 2.50
Deferred Finance Fees		$ 40,000
Discount for conversion feature and warrants/shares		$ 360,000
Convertible Notes [Member] | Convertible Debt Forty Seven [Member]
Lender		Clay 5/11/20 Loan
Inception Date		May 18, 2020
Term		12 months
Loan Amount		$ 546,250
Outstanding balance with OID		546,250
Original Issue Discount (OID)		$ 71,250
Interest Rate		10.00%
Conversion Price		$ 2.50
Deferred Finance Fees		$ 35,500
Discount for conversion feature and warrants/shares		$ 439,500
Convertible Notes [Member] | Convertible Debt Forty Eight [Member]
Lender		Clay 5/20/20 Loan
Inception Date		Jun. 2, 2020
Term		12 months
Loan Amount		$ 902,750
Outstanding balance with OID		902,750
Original Issue Discount (OID)		$ 117,750
Interest Rate		10.00%
Conversion Price		$ 2.50
Deferred Finance Fees		$ 58,900
Discount for conversion feature and warrants/shares		$ 708,500
Convertible Notes [Member] | Convertible Debt Forty Nine [Member]
Lender		Geer 6/1/20 Loan
Inception Date		May 29, 2020
Term		12 months
Loan Amount		$ 110,000
Outstanding balance with OID		110,000
Original Issue Discount (OID)		$ 10,000
Interest Rate		10.00%
Conversion Price		$ 2.50
Deferred Finance Fees
Discount for conversion feature and warrants/shares
Convertible Notes [Member] | Convertible Debt Fifty [Member]
Lender		Clay 6/12/20 Loan
Inception Date		Jun. 12, 2020
Term		12 months
Loan Amount		$ 57,500
Outstanding balance with OID		57,500
Original Issue Discount (OID)		$ 7,500
Interest Rate		10.00%
Conversion Price		$ 2.50
Deferred Finance Fees		$ 5,000
Discount for conversion feature and warrants/shares		$ 45,000
Convertible Notes [Member] | Convertible Debt Fifty One [Member]
Lender		Clay 6/22/20 Loan
Inception Date		Jun. 22, 2020
Term		12 months
Loan Amount		$ 138,000
Outstanding balance with OID		138,000
Original Issue Discount (OID)		$ 18,000
Interest Rate		10.00%
Conversion Price		$ 2.50
Deferred Finance Fees		$ 12,000
Discount for conversion feature and warrants/shares		$ 108,000
[1]	As of June 30, 2020 lender entered into a Standstill and Forbearance agreement (as described below). Loan is convertible at $2.50 until the expiration of the agreement.
[2]	During the six months ended June 30, 2020 the Company entered into Rate Modification Agreements with these lenders. In these agreements five lenders agreed to reduce their interest rate and were granted the right to convert loans using a variable conversion price if other variable rate lenders converted at a variable rate.
[3]	Interest was capitalized and added to outstanding principal.
[4]	The Note is past due. The Company and the lender are negotiating in good faith to extend the loan.

Convertible Debt and Other De_5

Convertible Debt and Other Debt - Summary of Changes in Convertible Debt, Net of Unamortized Discounts (Details)	6 Months Ended
	Jun. 30, 2020USD ($)
Debt Disclosure [Abstract]
Balance at January 1,	$ 6,121,338
Issuance of convertible debt, face value	5,435,950
Deferred financing cost	(1,013,350)
Contingent beneficial conversion feature on convertible note	(982,097)
Debt discount from warrants issued with debt	(2,705,996)
Payments	(1,257,250)
Conversion of debt into equity	(771,266)
Accretion of interest and amortization of debt discount to interest expense	1,397,121
Balance at March 31,	6,224,450
Less: current portion	6,224,450
Convertible debt, long-term portion

Convertible Debt and Other De_6

Convertible Debt and Other Debt - Schedule of Merchant Agreements (Details) - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2020	Dec. 31, 2019
Purchase Price	$ 1,400,000	$ 1,400,000
Purchased Amount	1,919,525	1,919,525
Outstanding Balance	690,838	1,082,435
Daily Payment	10,745	10,745
Deferred Finance Fees	$ 15,750	$ 15,750
Merchant Agreements One [Member]
Inception Date	Aug. 5, 2019	Aug. 5, 2019
Purchase Price	$ 600,000	$ 600,000
Purchased Amount	816,000	816,000
Outstanding Balance	174,943	421,024
Daily Payment	4,533	4,533
Deferred Finance Fees	$ 6,000	$ 6,000
Merchant Agreements Two [Member]
Inception Date	Aug. 19, 2019	Aug. 19, 2019
Purchase Price	$ 350,000	$ 350,000
Purchased Amount	479,500	479,500
Outstanding Balance	245,355	272,315
Daily Payment	2,664	2,664
Deferred Finance Fees	$ 3,000	$ 3,000
Merchant Agreements Three [Member]
Inception Date	Aug. 23, 2019	Aug. 23, 2019
Purchase Price	$ 175,000	$ 175,000
Purchased Amount	239,750	239,750
Outstanding Balance	87,192	132,284
Daily Payment	1,410	1,410
Deferred Finance Fees	$ 1,750	$ 1,750
Merchant Agreements Four [Member]
Inception Date	Sep. 19, 2019	Sep. 19, 2019
Purchase Price	$ 275,000	$ 275,000
Purchased Amount	384,275	384,275
Outstanding Balance	183,348	256,812
Daily Payment	2,138	2,138
Deferred Finance Fees	$ 5,000	$ 5,000

Stockholders' Deficit (Details

Stockholders' Deficit (Details Narrative) - USD ($)	3 Months Ended			6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Mar. 31, 2019	Jun. 30, 2020	Jun. 30, 2019	Mar. 31, 2020	Dec. 31, 2019	Nov. 29, 2015	Dec. 12, 2013
Preferred stock, authorized	1,000,000			1,000,000
Preferred stock, par value	$ 0.01			$ 0.01
Preferred stock, shares issued	1,000,000			1,000,000
Common stock, shares outstanding under the plan	14,153,496			14,153,496		11,289,336
Outstanding stock options	3,932
Stock issued during the period for conversion of debt principal and interest				$ 420,746
Stock issued during the period for conversion of debt principal and interest, shares				1,317,649
Number of common stock value issued for services rendered, value	$ 87,963		$ 168,000
Stock issued during the period conversion of convertible debt					65,377
Stock issued during the period conversion of convertible debt, value		$ 105,589	$ 50,733		$ 156,322
New Convertible Loans [Member]
Warrant to purchase shares of common stock	2,412,870			2,412,870
Fair value of warrants				$ 2,958,693
Stock Option [Member]
Common stock, shares outstanding under the plan	1,392,370			1,392,370		1,396,302
Outstanding stock options	3,932			442,391
Stock options, exercise price	$ 0.69			$ 0.69
Unvested Stock-Based Awards [Member]
Total unrecognized compensation cost	$ 589,652			$ 589,652
Unvested stock options weighted average period				1 year 7 months 10 days
Closing stock price	$ 2.30			$ 2.30
Aggregate intrinsic value of options outstanding and exercisable	$ 712,250			$ 712,250
Series AA Holders [Member]
Stock issued during the period				64,388	42,456
Stock issued during the period, value				$ 176,748	$ 105,941
Accredited Investor and Consultants [Member]
Number of restricted stock issued				593,277
Number of restricted stock issued during period, value				$ 1,693,251
Holders [Member]
Stock issued during the period for debt extensions and interest payments				$ 81,031
Stock issued during the period for debt extensions and interest payments, shares				159,784
Stock issued during the period conversion of convertible debt					47,599
Stock issued during the period conversion of convertible debt, value					$ 156,322
Consultants [Member]
Issuance of common stock for to settle accrued liabilities				$ 66,500
Issuance of common stock for to settle accrued liabilities, shares				127,855
Number of common stock value issued for services rendered				25,000	50,000
Number of common stock value issued for services rendered, value				$ 87,963	$ 168,000
Lenders [Member]
Warrant to purchase shares of common stock	495,000			495,000
Fair value of warrants				$ 969,745
Accredited Investor [Member]
Number of restricted stock issued					205,432
Number of restricted stock issued during period, value					$ 641,211
2013 Equity Incentive Plan [Member]
Common stock reserved for stock option plan									3,000,000
Common stock, shares outstanding under the plan	1,392,370			1,392,370
2015 Nonqualified Stock Option Plan [Member] | Board of Directors [Member]
Common stock reserved for stock option plan								5,000,000
Series A Junior Participating Preferred Stock [Member]
Preferred stock, authorized	20,000			20,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Series A Convertible Preferred Stock [Member]
Preferred stock, authorized	313,960			313,960
Preferred stock, shares issued
Preferred stock, shares outstanding
Series B Convertible Preferred Stock [Member]
Preferred stock, authorized	279,256			279,256
Preferred stock, shares issued
Preferred stock, shares outstanding
Series C Convertible Preferred Stock [Member]
Preferred stock, authorized	88,098			88,098
Preferred stock, shares issued
Preferred stock, shares outstanding
Series D Convertible Preferred Stock [Member]
Preferred stock, authorized	850			850			850
Preferred stock, par value	$ 0.01			$ 0.01			$ 0.01
Preferred stock, shares issued	300			300			300
Preferred stock, shares outstanding	300			300			300
Series E Convertible Preferred Stock [Member]
Preferred stock, authorized	500			500
Preferred stock, shares issued
Preferred stock, shares outstanding
Series G Convertible Preferred Stock [Member]
Preferred stock, authorized	240,000			240,000			240,000
Preferred stock, par value	$ 0.01			$ 0.01			$ 0.01
Preferred stock, shares issued	80,570			80,570			80,570
Preferred stock, shares outstanding	80,570			80,570			80,570
Series H Convertible Preferred Stock [Member]
Preferred stock, authorized	10,000			10,000			10,000
Preferred stock, par value	$ 0.01			$ 0.01			$ 0.01
Preferred stock, shares issued	10,000			10,000			10,000
Preferred stock, shares outstanding	10,000			10,000			10,000
Series H2 Convertible Preferred Stock [Member]
Preferred stock, authorized	21			21			21
Preferred stock, par value	$ 0.01			$ 0.01			$ 0.01
Preferred stock, shares issued	21			21			21
Preferred stock, shares outstanding	21			21			21
Series J Convertible Preferred Stock [Member]
Preferred stock, authorized	6,250			6,250			6,250
Preferred stock, par value	$ 0.01			$ 0.01			$ 0.01
Preferred stock, shares issued	3,458			3,458			3,458
Preferred stock, shares outstanding	3,458			3,458			3,458
Series K Convertible Preferred Stock [Member]
Preferred stock, authorized	15,000			15,000			15,000
Preferred stock, par value	$ 0.01			$ 0.01			$ 0.01
Preferred stock, shares issued	6,880			6,880			6,880
Preferred stock, shares outstanding	6,880			6,880			6,880
Series AA Convertible Preferred Stock [Member]
Preferred stock, authorized	10,000			10,000			10,000
Preferred stock, par value	$ 0.01			$ 0.01			$ 0.01
Preferred stock, shares issued	7,939			7,939			7,939
Preferred stock, shares outstanding	7,939			7,939			7,939

Stockholders' Deficit - Schedul

Stockholders' Deficit - Schedule of Concerning Options and Warrants Outstanding and Exercisable (Details) - $ / shares	3 Months Ended	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2020
Shares, Beginning balance	11,289,336
Shares, Granted	2,907,870
Shares, Exercised
Shares, Expired	(39,778)
Shares, Forfeited	(3,932)
Shares, Ending balance	14,153,496	14,153,496
Exercisable, Beginning balance	10,148,543
Exercisable, Ending balance	13,203,517	13,203,517
Stock Option [Member]
Shares, Beginning balance	1,396,302
Shares, Granted
Shares, Exercised
Shares, Expired
Shares, Forfeited	(3,932)	(442,391)
Shares, Ending balance	1,392,370	1,392,370
Weighted average price per share, Beginning balance	$ 0.71
Weighted average price per share, Granted
Weighted average price per share, Exercised
Weighted average price per share, Expired
Weighted average price per share, Forfeited	0.69
Weighted average price per share, Ending balance	$ 0.69	$ 0.69
Warrants [Member]
Shares, Beginning balance	9,893,034
Shares, Granted	2,907,870
Shares, Exercised	2,907,870
Shares, Expired	(39,778)
Shares, Forfeited
Shares, Ending balance	12,761,126	12,761,126
Weighted average price per share, Beginning balance	$ 3.52
Weighted average price per share, Granted	3.50
Weighted average price per share, Exercised
Weighted average price per share, Expired	8.40
Weighted average price per share, Forfeited
Weighted average price per share, Ending balance	$ 3.50	$ 3.50

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)	Jul. 07, 2020	Aug. 12, 2020	Jun. 30, 2020	Jun. 30, 2019
Convertible loans paid			$ 1,257,250	$ 2,533,985
Debt instrument face value			$ 5,435,950
Subsequent Event [Member]
Debt instrument conversion price		$ 2.50
Debt instrument convertible into shares		$ 1,700,000
Interest rate		10.00%
Debt term		1 year
Number of convertible debt shares issued		22,500
Warrants exercisable into common shares		595,700
Warrant term		5 years
Warrant exercise price		$ 3.50
Convertible loans paid		$ 702,800
Convertible loans description		During this period, the Company also paid off five convertible loans totaling $702,800. The loans were issued July 19, 2018, April 9, 2019, July 29, 2019, August 6, 2019 and October 8, 2019.
Company paid amount to retire loans		$ 472,371
Subsequent Event [Member] | Standstill and Forbearance Agreements [Member] | Lender [Member]
Debt instrument face value		$ 1,970,000
Subsequent Event [Member] | Standstill and Forbearance Agreements [Member] | Merchant Lenders [Member]
Warrant term	3 years
Warrant exercise price	$ 3.50
Number of shares issued during the period	112,885
Number of shares issued during the period, value	$ 385,388
Subsequent Event [Member] | Standstill and Forbearance Agreements [Member] | Merchant Lenders [Member] | Warrants [Member]
Number of shares issued during the period	112,885
Subsequent Event [Member] | For Partial Settlement of Principal and Fees on Loan [Member]
Number of shares issued during the period		24,000
Debt principal and fees, value		$ 54,397
Subsequent Event [Member] | Convertible Loans Principal [Member]
Warrant term		3 years
Warrant exercise price		$ 3.50
Number of shares issued during the period		248,898
Warrant to acquire common stock shares		103,469